is	O
well	O
known	O
.	O
We	O
have	O
recently	O
described	O
enhanced	O
expression	O
of	O
IFN-alpha	B-protein
in	O
the	O
mucosa	O
of	O
patients	O
with	O
celiac	O
disease	O
(	O
CD	O
)	O
,	O
a	O
gluten-sensitive	O
Th1-mediated	O
enteropathy	O
,	O
characterized	O
by	O
villous	O
atrophy	O
and	O
crypt	O
cell	O
hyperplasia	O
.	O
Previous	O
studies	O
from	O
this	O
laboratory	O
have	O
shown	O
that	O
T	O
cell	O
activation	O
in	O
explant	O
cultures	O
of	O
human	O
fetal	O
gut	O
can	O
also	O
result	O
in	O
villous	O
atrophy	O
and	O
crypt	O
cell	O
hyperplasia	O
.	O
We	O
have	O
,	O
therefore	O
,	O
examined	O
changes	O
that	O
take	O
place	O
in	O
explant	O
cultures	O
of	O
human	O
fetal	O
gut	O
after	O
activation	O
of	O
T	O
cells	O
with	O
anti-CD3	O
and/or	O
IFN-alpha	B-protein
.	O
We	O
show	O
that	O
activation	O
of	O
T	O
cells	O
with	O
anti-CD3	O
alone	O
elicits	O
a	O
small	O
IFN-gamma	O
and	O
TNF-alpha	O
response	O
with	O
no	O
tissue	O
injury	O
.	O
Similarly	O
,	O
no	O
changes	O
are	O
seen	O
in	O
explants	O
cultured	O
with	O
IFN-alpha	B-protein
alone	O
.	O
However	O
,	O
addition	O
of	O
IFN-alpha	B-protein
with	O
anti-CD3	O
results	O
in	O
enhanced	O
Th1	O
response	O
and	O
crypt	O
cell	O
hyperplasia	O
.	O
This	O
is	O
associated	O
with	O
enhanced	O
phosphorylation	O
of	O
STAT1	B-protein
,	O
STAT3	B-protein
,	O
and	O
Fyn	B-protein
,	O
a	O
Src	B-protein
homology	I-protein
tyrosine	I-protein
kinase	I-protein
,	O
which	O
interacts	O
with	O
both	O
TCR	B-protein
and	O
IFN-alpha	O
signal	O
components	O
.	O
Together	O
these	O
data	O
indicate	O
that	O
IFN-alpha	B-protein
can	O
facilitate	O
activation	O
of	O
Th1-reactive	O
cells	O
in	O
the	O
gut	O
and	O
drive	O
immunopathology	O
.	O
Suppression	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	O
production	O
by	O
cAMP	O
in	O
human	O
monocytes	O
:	O
dissociation	O
with	O
mRNA	O
level	O
and	O
independent	O
of	O
interleukin-10	B-protein
.	O
BACKGROUND	O
:	O
Elevation	O
of	O
cellular	O
cAMP	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
production	O
and	O
increases	O
the	O
expression	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
in	O
mononuclear	O
cells	O
.	O
TNF-alpha	O
gene	O
expression	O
obligates	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O
Exogenous	O
IL-10	O
inhibits	O
NF-kappaB	B-protein
in	O
monocytes	O
and	O
thus	O
attenuates	O
TNF-alpha	O
production	O
.	O
We	O
examined	O
the	O
role	O
of	O
endogenous	O
IL-10	B-protein
in	O
the	O
regulation	O
of	O
NF-kappaB	B-protein
activation	O
and	O
TNF-alpha	B-protein
production	O
in	O
human	O
monocytes	O
by	O
cAMP	O
.	O
METHODS	O
:	O
Human	O
monocytes	O
were	O
stimulated	O
with	O
Escherichia	O
coli	O
LPS	O
(	O
100	O
ng/ml	O
)	O
with	O
and	O
without	O
forskolin	O
(	O
FSK	O
,	O
50	O
microM	O
)	O
or	O
dibutyryl	O
cyclic	O
AMP	O
(	O
dbcAMP	O
,	O
100	O
microM	O
)	O
.	O
Cytokine	B-protein
(	O
TNF-alpha	B-protein
and	O
IL-10	B-protein
)	O
release	O
was	O
measured	O
by	O
immunoassay	O
.	O
TNF-alpha	O
mRNA	O
was	O
measured	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
,	O
and	O
NF-kappaB	B-protein
DNA	O
binding	O
activity	O
was	O
assessed	O
by	O
gel	O
mobility	O
shift	O
assay	O
.	O
RESULTS	O
:	O
cAMP-elevating	O
agents	O
inhibited	O
LPS-stimulated	O
TNF-alpha	O
release	O
(	O
0.77	O
+/-	O
0.13	O
ng/10	O
(	O
6	O
)	O
cells	O
in	O
LPS	O
+	O
dbcAMP	O
and	O
0.68	O
+/-	O
0.19	O
ng/10	O
(	O
6	O
)	O
cells	O
in	O
LPS	O
+	O
FSK	O
,	O
both	O
P	O
<	O
0.05	O
vs	O
1.61	O
+/-	O
0.34	O
ng/10	O
(	O
6	O
)	O
cells	O
in	O
LPS	O
alone	O
)	O
.	O
Conversely	O
,	O
cAMP	O
enhanced	O
LPS-stimulated	O
IL-10	O
release	O
(	O
100	O
+/-	O
21.5	O
pg/10	O
(	O
6	O
)	O
cells	O
in	O
LPS	O
+	O
dbcAMP	O
and	O
110	O
+/-	O
25.2	O
pg/10	O
(	O
6	O
)	O
cells	O
in	O
LPS	O
+	O
FSK	O
,	O
both	O
P	O
<	O
0.05	O
vs	O
53.3	O
+/-	O
12.8	O
pg/10	O
(	O
6	O
)	O
cells	O
in	O
LPS	O
alone	O
)	O
.	O
Neither	O
TNF-alpha	O
mRNA	O
expression	O
nor	O
NF-kappaB	O
activation	O
stimulated	O
by	O
LPS	O
was	O
inhibited	O
by	O
the	O
cAMP-elevating	O
agents	O
.	O
Neutralization	O
of	O
IL-10	B-protein
with	O
a	O
specific	B-protein
antibody	I-protein
did	O
not	O
attenuate	O
the	O
effect	O
of	O
cAMP-elevating	O
agents	O
on	O
TNF-alpha	B-protein
production	O
.	O
CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
cAMP	O
inhibits	O
LPS-stimulated	O
TNF-alpha	O
production	O
through	O
a	O
posttranscriptional	O
mechanism	O
that	O
is	O
independent	O
of	O
endogenous	O
IL-10	B-protein
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
Activation	O
of	O
the	O
p21	O
(	O
CIP1/WAF1	O
)	O
promoter	O
by	O
bone	O
morphogenetic	O
protein-2	O
in	O
mouse	O
B	O
lineage	O
cells	O
.	O
BMPs	O
exert	O
a	O
negative	O
growth	O
effect	O
on	O
various	O
types	O
of	O
cells	O
.	O
We	O
have	O
previously	O
reported	O
that	O
BMP-2	B-protein
inhibited	O
the	O
growth	O
of	O
HS-72	O
mouse	O
hybridoma	O
cells	O
by	O
inducing	O
p21	O
(	O
CIP1/WAF1	O
)	O
expression	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
BMP-2	O
activated	O
the	O
mouse	O
p21	O
(	O
CIP1/WAF1	O
)	O
promoter	O
in	O
HS-72	O
cells	O
,	O
and	O
that	O
a	O
29-base	O
pair	O
(	O
b	O
)	O
region	O
of	O
the	O
promoter	O
(	O
-1928/-1900	O
relative	O
to	O
the	O
TATA	O
box	O
)	O
,	O
conserved	O
between	O
mice	O
and	O
humans	O
,	O
was	O
responsive	O
to	O
BMP-2	B-protein
as	O
well	O
as	O
expression	O
of	O
Smad1	O
,	O
Smad4	B-protein
,	O
and	O
constitutively	O
active	O
mutants	O
of	O
BMP	B-protein
type	I-protein
I	I-protein
receptors	I-protein
.	O
Furthermore	O
,	O
an	O
oligonucleotide	O
containing	O
the	O
29-b	O
region	O
was	O
found	O
to	O
be	O
associated	O
with	O
Smad4	B-protein
and	O
phosphorylated	O
Smad1	O
in	O
the	O
nuclear	O
extract	O
of	O
BMP-2	B-protein
-stimulated	O
HS-72	O
cells	O
.	O
These	O
results	O
suggested	O
that	O
BMP-2	B-protein
might	O
activate	O
p21	O
(	O
CIP1/WAF1	O
)	O
transcription	O
by	O
inducing	O
a	O
binding	O
of	O
Smad4	B-protein
and	O
Smad1	O
to	O
the	O
29-b	O
region	O
in	O
HS-72	O
cells	O
.	O
Dendritic	O
cell	O
development	O
from	O
common	O
myeloid	O
progenitors	O
.	O
Dendritic	O
cells	O
(	O
DCs	O
)	O
are	O
professional	O
antigen-presenting	O
cells	O
which	O
both	O
initiate	O
adaptive	O
immune	O
responses	O
and	O
control	O
tolerance	O
to	O
self-antigens	O
.	O
It	O
has	O
been	O
suggested	O
that	O
these	O
different	O
effects	O
on	O
responder	O
cells	O
depend	O
on	O
subsets	O
of	O
DCs	O
arising	O
from	O
either	O
myeloid	O
or	O
lymphoid	O
hematopoietic	O
origins	O
.	O
In	O
this	O
model	O
,	O
CD8	O
alpha+	O
Mac-1-	O
DCs	O
are	O
supposed	O
to	O
be	O
of	O
lymphoid	O
while	O
CD8	O
alpha-	O
Mac-1+	O
DCs	O
are	O
supposed	O
to	O
be	O
of	O
myeloid	O
origin	O
.	O
Here	O
we	O
summarize	O
our	O
findings	O
that	O
both	O
CD8	O
alpha+	O
and	O
CD8	O
alpha-	O
DCs	O
can	O
arise	O
from	O
clonogenic	O
common	O
myeloid	O
progenitors	O
(	O
CMPs	O
)	O
in	O
both	O
thymus	O
and	O
spleen	O
.	O
Therefore	O
CD8	O
alpha	O
expression	O
DCs	O
does	O
not	O
indicate	O
a	O
lymphoid	O
origin	O
and	O
differences	O
among	O
CD8	O
alpha+	O
and	O
CD8	O
alpha-	O
DCs	O
might	O
rather	O
reflect	O
maturation	O
status	O
than	O
ontogeny	O
.	O
On	O
the	O
basis	O
of	O
transplantation	O
studies	O
,	O
it	O
seems	O
likely	O
that	O
most	O
of	O
the	O
DCs	O
in	O
secondary	O
lymphoid	O
organs	O
and	O
a	O
substantial	O
fraction	O
of	O
thymic	O
DCs	O
are	O
myeloid-derived	O
.	O
Macrophage	O
stimulation	O
with	O
Murabutide	O
,	O
an	O
HIV-suppressive	O
muramyl	O
peptide	O
derivative	O
,	O
selectively	O
activates	O
extracellular	B-protein
signal-regulated	I-protein
kinases	I-protein
1	I-protein
and	I-protein
2	I-protein
,	O
C/EBPbeta	O
and	O
STAT1	O
:	O
role	O
of	O
CD14	B-protein
and	O
Toll-like	B-protein
receptors	I-protein
2	O
and	O
4	O
.	O
The	O
smallest	O
unit	O
of	O
bacterial	O
peptidoglycans	O
known	O
to	O
be	O
endowed	O
with	O
biological	O
activities	O
is	O
muramyl	O
dipeptide	O
(	O
MDP	O
)	O
.	O
A	O
clinically	O
acceptable	O
synthetic	O
derivative	O
of	O
MDP	O
,	O
namely	O
murabutide	O
(	O
MB	O
)	O
,	O
has	O
been	O
found	O
to	O
present	O
interesting	O
pharmacological	O
properties	O
and	O
to	O
suppress	O
HIV-1	O
replication	O
in	O
monocyte-derived	O
macrophages	O
(	O
MDM	O
)	O
.	O
We	O
have	O
addressed	O
the	O
signaling	O
events	O
activated	O
in	O
MDM	O
following	O
stimulation	O
with	O
either	O
MB	B-protein
or	O
the	O
potent	O
immunostimulant	O
LPS	O
.	O
We	O
also	O
examined	O
whether	O
signaling	O
by	O
muramyl	O
peptides	O
involves	O
the	O
use	O
of	O
cell	B-protein
surface	I-protein
receptors	I-protein
,	O
including	O
CD14	B-protein
and	O
Toll-like	B-protein
receptor	I-protein
2	I-protein
(	O
TLR2	O
)	O
or	O
TLR4	O
that	O
are	O
known	O
to	O
be	O
signal-transducing	O
receptors	O
for	O
other	O
bacterial	O
cell	O
wall	O
components	O
.	O
We	O
demonstrate	O
that	O
,	O
unlike	O
LPS	O
,	O
the	O
safe	O
immunomodulator	O
MB	O
selectively	O
activates	O
extracellular	B-protein
signal-regulated	I-protein
kinases	I-protein
(	O
Erk	B-protein
)	O
1/2	O
,	O
in	O
the	O
absence	O
of	O
detectable	B-protein
Jun	I-protein
N-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
or	O
p38	B-protein
mitogen-activated	O
kinase	O
activation	O
.	O
Furthermore	O
,	O
STAT1	O
activation	O
but	O
weak	O
or	O
no	O
activation	O
of	O
STAT3	B-protein
or	O
STAT5	B-protein
respectively	O
,	O
could	O
be	O
detected	O
in	O
MB-stimulated	O
MDM	O
.	O
Using	O
MonoMac6	O
cells	O
,	O
we	O
observed	O
high	O
C/EBPbeta	O
and	O
AP-1	B-protein
but	O
weaker	O
and	O
transient	O
NF-kappaB	O
activation	O
by	O
MB	O
.	O
Moreover	O
,	O
the	O
truncated	O
form	O
of	O
C/EBPbeta	O
,	O
known	O
to	O
repress	O
HIV-1	O
transcription	O
,	O
was	O
detected	O
in	O
extracts	O
from	O
MB-treated	O
THP-1	O
cells	O
.	O
Surprisingly	O
,	O
neither	O
MB	O
nor	O
MDP	O
were	O
able	O
to	O
transduce	O
signals	O
via	O
CD14	B-protein
and	O
TLR2	O
or	O
4	O
.	O
These	O
findings	O
present	O
major	O
differences	O
in	O
the	O
early	O
cell	O
activation	O
process	O
between	O
LPS	O
and	O
muramyl	O
peptides	O
,	O
and	O
strongly	O
argue	O
for	O
the	O
implication	O
of	O
co-receptors	O
other	O
than	O
TLR2	O
and	O
TLR4	O
in	O
mediating	O
the	O
signaling	O
events	O
induced	O
by	O
defined	O
subunits	O
of	O
bacterial	O
peptidoglycans	O
.	O
Nuclear	O
peroxisome	O
proliferator-activated	O
receptors	O
alpha	O
and	O
gamma	O
have	O
opposing	O
effects	O
on	O
monocyte	O
chemotaxis	O
in	O
endometriosis	O
.	O
The	O
peroxisome	B-protein
proliferator-activated	I-protein
receptors	I-protein
(	O
PPARs	B-protein
)	I-protein
alpha	I-protein
and	I-protein
gamma	I-protein
are	I-protein
nuclear	I-protein
receptors	I-protein
that	O
play	O
important	O
roles	O
in	O
inflammatory	O
diseases	O
like	O
ulcerative	O
colitis	O
and	O
arthritis	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
possible	O
role	O
of	O
PPARs	B-protein
in	O
macrophage	O
attraction	O
into	O
the	O
peritoneal	O
cavity	O
of	O
patients	O
with	O
endometriosis	O
.	O
We	O
identified	O
PPAR-alpha	O
and	O
-gamma	O
messenger	O
RNA	O
by	O
RT-PCR	O
and	O
protein	O
by	O
immunoblotting	O
of	O
lysates	O
of	O
peritoneal	O
macrophages	O
and	O
monocytic	O
U937	O
cells	O
.	O
Using	O
immunocytochemistry	O
,	O
we	O
localized	O
PPAR-alpha	B-protein
and	I-protein
-gamma	I-protein
within	O
the	O
nuclei	O
of	O
both	O
cell	O
types	O
.	O
Monocyte	O
chemotactic	O
activity	O
of	O
peritoneal	O
fluid	O
from	O
patients	O
with	O
endometriosis	O
was	O
quantified	O
in	O
Boyden	O
chambers	O
.	O
Migration	O
of	O
U937	O
cells	O
was	O
increased	O
by	O
WY	O
14643	O
and	O
reduced	O
by	O
rosiglitazone	O
.	O
Peritoneal	O
fluid	O
from	O
patients	O
with	O
endometriosis	O
activated	O
U937	O
cells	O
transiently	O
transfected	O
with	O
a	O
PPAR-alpha/GAL4	O
luciferase	O
reporter	O
.	O
By	O
contrast	O
,	O
peritoneal	O
fluid	O
did	O
not	O
cause	O
significant	O
activation	O
of	O
PPAR-gamma/GAL4	O
constructs	O
.	O
The	O
U937	O
cells	O
transiently	O
transfected	O
with	O
a	O
PPAR	O
response	O
element	O
luciferase	O
reporter	O
showed	O
disease	O
stage-dependent	O
up-regulation	O
when	O
treated	O
with	O
peritoneal	O
fluid	O
from	O
patients	O
with	O
endometriosis	O
.	O
Treatment	O
with	O
peritoneal	O
fluid	O
from	O
healthy	O
controls	O
down-regulated	O
PPAR	O
response	O
element	O
transactivation	O
.	O
We	O
conclude	O
that	O
peritoneal	O
fluid	O
of	O
endometriosis	O
patients	O
contains	O
activators	O
of	O
PPAR-alpha	O
that	O
stimulate	O
macrophage	O
chemotaxis	O
.	O
Inhibitors	O
of	O
PPAR-alpha	B-protein
or	I-protein
activators	I-protein
of	I-protein
PPAR-gamma	I-protein
could	O
be	O
developed	O
for	O
the	O
treatment	O
of	O
inflammation	O
associated	O
with	O
endometriosis	O
.	O
Long-term-impaired	O
expression	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
trauma	O
patients	O
.	O
Nuclear	B-protein
factor	I-protein
(	O
NF	O
)	O
-kappa	O
B	O
expression	O
and	O
dimer	O
characteristics	O
were	O
studied	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
of	O
major-trauma	O
patients	O
and	O
healthy	O
controls	O
.	O
Analysis	O
of	O
PBMCs	O
on	O
days	O
1	O
,	O
3	O
,	O
5	O
,	O
and	O
10	O
after	O
trauma	O
revealed	O
that	O
expression	O
of	O
both	O
p65p50	O
heterodimers	O
and	O
p50p50	O
homodimers	O
was	O
significantly	O
reduced	O
compared	O
with	O
that	O
in	O
controls	O
.	O
In	O
vitro	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
of	O
PBMCs	O
induced	O
NF-kappa	B-protein
B	I-protein
translocation	O
.	O
However	O
,	O
throughout	O
the	O
survey	O
,	O
p65p50	O
activation	O
remained	O
significantly	O
lower	O
in	O
trauma	O
patients	O
than	O
in	O
controls	O
.	O
After	O
LPS	O
stimulation	O
in	O
vitro	O
,	O
the	O
p65p50/p50p50	O
ratio	O
was	O
significantly	O
lower	O
in	O
PBMCs	O
from	O
trauma	O
patients	O
than	O
from	O
healthy	O
controls	O
.	O
The	O
ex	O
vivo	O
expression	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
was	O
higher	O
in	O
PBMCs	O
of	O
controls	O
than	O
of	O
trauma	O
patients	O
.	O
LPS	O
did	O
not	O
induce	O
I	O
kappa	O
B	O
expression	O
in	O
PBMCs	O
from	O
trauma	O
patients	O
,	O
but	O
strong	O
induction	O
was	O
obtained	O
with	O
staphylococci	O
,	O
suggesting	O
that	O
this	O
defect	O
is	O
not	O
universal	O
and	O
depends	O
on	O
the	O
nature	O
of	O
the	O
activating	O
signal	O
.	O
Although	O
no	O
direct	O
correlation	O
was	O
found	O
between	O
levels	O
of	O
interleukin-10	B-protein
or	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
and	O
NF-kappa	B-protein
B	I-protein
,	O
these	O
immunosuppressive	B-protein
cytokines	I-protein
were	O
significantly	O
elevated	O
in	O
trauma	O
patients	O
by	O
10	O
days	O
after	O
admission	O
.	O
The	O
long-term	O
low-basal	O
and	O
LPS-induced	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
recalled	O
long-term	O
immunoparalysis	O
observed	O
in	O
patients	O
with	O
severe	O
inflammatory	O
stress	O
such	O
as	O
trauma	O
.	O
Hepatic	O
ischemia-reperfusion	O
injury	O
.	O
BACKGROUND	O
:	O
The	O
morbidity	O
associated	O
with	O
liver	O
transplantation	O
and	O
major	O
hepatic	O
resections	O
is	O
partly	O
a	O
result	O
of	O
ischemia-reperfusion	O
injury	O
.	O
DATA	O
SOURCES	O
:	O
The	O
entire	O
world	O
literature	O
on	O
the	O
subject	O
was	O
searched	O
via	O
Medline	O
.	O
Keywords	O
included	O
reperfusion	O
injury	O
,	O
transplantation	O
,	O
liver	O
resection	O
,	O
nitric	O
oxide	O
,	O
endothelin	O
,	O
cytokines	B-protein
,	O
Kupffer	O
cells	O
,	O
ischemic/ischaemic	O
preconditioning	O
,	O
and	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
.	O
CONCLUSIONS	O
:	O
An	O
imbalance	O
between	O
endothelin	O
and	O
nitric	O
oxide	O
levels	O
results	O
in	O
failure	O
of	O
the	O
hepatic	O
microcirculation	O
at	O
the	O
onset	O
of	O
reperfusion	O
.	O
Activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
in	O
the	O
liver	O
promotes	O
proinflammatory	B-protein
cytokine	I-protein
and	O
adhesion	O
molecule	O
synthesis	O
.	O
These	O
result	O
in	O
oxygen-derived	O
free	O
radical	O
production	O
and	O
neutrophil	O
recruitment	O
,	O
further	O
contributing	O
to	O
cellular	O
injury	O
.	O
Various	O
therapeutic	O
modalities	O
acting	O
on	O
the	O
above	O
mediators	O
have	O
been	O
successfully	O
used	O
to	O
attenuate	O
reperfusion	O
injury	O
in	O
animal	O
models	O
of	O
hepatic	O
transplantation	O
and	O
resection	O
.	O
Application	O
of	O
the	O
knowledge	O
gained	O
from	O
animal	O
models	O
of	O
hepatic	O
ischemia-reperfusion	O
to	O
the	O
clinical	O
setting	O
will	O
improve	O
the	O
outcome	O
of	O
hepatic	O
surgery	O
.	O
Down-regulation	O
of	O
IL-12	B-protein
p40	O
gene	O
in	O
Plasmodium	O
berghei-infected	O
mice	O
.	O
We	O
analyzed	O
the	O
mechanism	O
that	O
causes	O
suppression	O
of	O
IL-12	B-protein
p40	O
gene	O
induction	O
during	O
Plasmodium	O
berghei	O
infection	O
.	O
Although	O
IL-12	B-protein
together	O
with	O
IFN-gamma	B-protein
plays	O
an	O
important	O
role	O
in	O
protection	O
against	O
pathogenic	O
infection	O
,	O
the	O
IL-12	B-protein
p70	I-protein
protein	I-protein
production	O
of	O
infected	O
macrophages	O
is	O
lower	O
than	O
that	O
by	O
the	O
uninfected	O
macrophages	O
.	O
We	O
showed	O
in	O
the	O
present	O
study	O
that	O
the	O
induction	O
of	O
IL-12	B-protein
p40	O
gene	O
but	O
not	O
IL-12	B-protein
p35	O
gene	O
in	O
macrophages	O
of	O
P.	O
berghei-infected	O
mice	O
was	O
profoundly	O
inhibited	O
.	O
The	O
inhibition	O
was	O
induced	O
by	O
interaction	O
with	O
macrophages	O
that	O
had	O
contacted	O
with	O
P.	O
berghei-infected	O
erythrocytes	O
and	O
was	O
mediated	O
by	O
a	O
soluble	B-protein
factor	I-protein
,	O
IL-10	B-protein
.	O
There	O
was	O
comparable	O
activation	O
of	O
NF-kappaB	B-protein
in	O
uninfected	O
and	O
infected	O
cells	O
.	O
The	O
induction	O
of	O
IFN-regulatory	O
factor-1	O
gene	O
was	O
comparable	O
in	O
transcription	O
level	O
in	O
uninfected	O
and	O
infected	O
cells	O
,	O
while	O
the	O
unidentified	O
complex	O
formation	O
of	O
IFN-regulatory	B-protein
factor-1	I-protein
was	O
observed	O
in	O
infected	O
cells	O
.	O
Therefore	O
,	O
the	O
inhibition	O
of	O
the	O
IL-12	O
p40	O
gene	O
induction	O
appeared	O
to	O
be	O
regulated	O
at	O
transcriptional	O
regulation	O
level	O
of	O
the	O
gene	O
.	O
The	O
Friend	O
of	O
GATA	B-protein
proteins	I-protein
U-shaped	O
,	O
FOG-1	O
,	O
and	O
FOG-2	O
function	O
as	O
negative	O
regulators	O
of	O
blood	O
,	O
heart	O
,	O
and	O
eye	O
development	O
in	O
Drosophila	O
.	O
Friend	O
of	O
GATA	B-protein
(	I-protein
FOG	I-protein
)	I-protein
proteins	I-protein
regulate	O
GATA	O
factor-activated	O
gene	O
transcription	O
.	O
During	O
vertebrate	O
hematopoiesis	O
,	O
FOG	O
and	O
GATA	B-protein
proteins	I-protein
cooperate	O
to	O
promote	O
erythrocyte	O
and	O
megakaryocyte	O
differentiation	O
.	O
The	O
Drosophila	O
FOG	O
homologue	O
U-shaped	O
(	O
Ush	O
)	O
is	O
expressed	O
similarly	O
in	O
the	O
blood	O
cell	O
anlage	O
during	O
embryogenesis	O
.	O
During	O
hematopoiesis	O
,	O
the	O
acute	O
myeloid	O
leukemia	O
1	O
homologue	O
Lozenge	O
and	O
Glial	O
cells	O
missing	O
are	O
required	O
for	O
the	O
production	O
of	O
crystal	O
cells	O
and	O
plasmatocytes	O
,	O
respectively	O
.	O
However	O
,	O
additional	O
factors	O
have	O
been	O
predicted	O
to	O
control	O
crystal	O
cell	O
proliferation	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
Ush	O
is	O
expressed	O
in	O
hemocyte	O
precursors	O
and	O
plasmatocytes	O
throughout	O
embryogenesis	O
and	O
larval	O
development	O
,	O
and	O
the	O
GATA	B-protein
factor	I-protein
Serpent	I-protein
is	O
essential	O
for	O
Ush	O
embryonic	O
expression	O
.	O
Furthermore	O
,	O
loss	O
of	O
ush	O
function	O
results	O
in	O
an	O
overproduction	O
of	O
crystal	O
cells	O
,	O
whereas	O
forced	O
expression	O
of	O
Ush	O
reduces	O
this	O
cell	O
population	O
.	O
Murine	O
FOG-1	O
and	O
FOG-2	B-protein
also	O
can	O
repress	O
crystal	O
cell	O
production	O
,	O
but	O
a	O
mutant	O
version	O
of	O
FOG-2	O
lacking	O
a	O
conserved	O
motif	O
that	O
binds	O
the	O
corepressor	B-protein
C-terminal	I-protein
binding	I-protein
protein	I-protein
fails	O
to	O
affect	O
the	O
cell	O
lineage	O
.	O
The	O
GATA	B-protein
factor	I-protein
Pannier	I-protein
(	O
Pnr	O
)	O
is	O
required	O
for	O
eye	O
and	O
heart	O
development	O
in	O
Drosophila	O
.	O
When	O
Ush	O
,	O
FOG-1	O
,	O
FOG-2	O
,	O
or	O
mutant	O
FOG-2	O
is	O
coexpressed	O
with	O
Pnr	O
during	O
these	O
developmental	O
processes	O
,	O
severe	O
eye	O
and	O
heart	O
phenotypes	O
result	O
,	O
consistent	O
with	O
a	O
conserved	O
negative	O
regulation	O
of	O
Pnr	O
function	O
.	O
These	O
results	O
indicate	O
that	O
the	O
fly	O
and	O
mouse	O
FOG	O
proteins	O
function	O
similarly	O
in	O
three	O
distinct	O
cellular	O
contexts	O
in	O
Drosophila	O
,	O
but	O
may	O
use	O
different	O
mechanisms	O
to	O
regulate	O
genetic	O
events	O
in	O
blood	O
vs	O
.	O
cardial	O
or	O
eye	O
cell	O
lineages	O
The	O
RING	B-protein
finger	I-protein
protein	I-protein
Siah-1	I-protein
regulates	O
the	O
level	O
of	O
the	O
transcriptional	O
coactivator	O
OBF-1	O
.	O
The	O
transcriptional	O
coactivator	O
OBF-1	O
,	O
which	O
interacts	O
with	O
Oct-1	O
and	O
Oct-2	O
and	O
the	O
octamer	O
site	O
DNA	O
,	O
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
development	O
of	O
a	O
normal	O
immune	O
response	O
and	O
the	O
formation	O
of	O
germinal	O
centers	O
in	O
secondary	O
lymphoid	O
organs	O
.	O
Here	O
we	O
have	O
identified	O
the	O
RING	O
finger	O
protein	O
Siah-1	O
as	O
a	O
protein	O
interacting	O
specifically	O
with	O
OBF-1	O
.	O
This	O
interaction	O
is	O
mediated	O
by	O
the	O
C-terminal	O
part	O
of	O
Siah-1	O
and	O
by	O
residues	O
in	O
the	O
N-terminus	O
of	O
OBF-1	O
,	O
partly	O
distinct	O
from	O
the	O
residues	O
required	O
for	O
formation	O
of	O
a	O
complex	O
with	O
the	O
Oct	O
POU	O
domains	O
and	O
the	O
DNA	O
.	O
Interaction	O
between	O
Siah-1	O
and	O
OBF-1	B-protein
leads	O
to	O
downregulation	O
of	O
OBF-1	B-protein
protein	I-protein
level	O
but	O
not	O
mRNA	O
,	O
and	O
to	O
a	O
corresponding	O
reduction	O
in	O
octamer	O
site-dependent	O
transcription	O
activation	O
.	O
Inhibition	O
of	O
the	O
ubiquitin-proteasome	O
pathway	O
in	O
B	O
cells	O
leads	O
to	O
elevated	O
levels	O
of	O
OBF-1	B-protein
protein	I-protein
.	O
Furthermore	O
,	O
in	O
immunized	O
mice	O
,	O
OBF-1	O
protein	O
amounts	O
are	O
dramatically	O
increased	O
in	O
primary	O
activated	O
B	O
cells	O
,	O
without	O
concomitant	O
increase	O
in	O
OBF-1	O
mRNA	O
.	O
These	O
data	O
suggest	O
that	O
Siah-1	O
is	O
part	O
of	O
a	O
novel	O
regulatory	O
loop	O
controlling	O
the	O
level	O
of	O
OBF-1	B-protein
protein	I-protein
in	O
B	O
cells	O
.	O
The	O
beta-catenin	O
--	O
TCF-1	B-protein
pathway	O
ensures	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocyte	O
survival	O
.	O
The	O
association	O
of	O
trans-acting	B-protein
T	I-protein
cell	I-protein
factors	I-protein
(	O
TCFs	O
)	O
or	O
lymphoid	B-protein
enhancer	I-protein
factor	I-protein
1	I-protein
(	O
LEF-1	O
)	O
with	O
their	O
coactivator	O
beta-catenin	O
mediates	O
transient	O
transcriptional	O
responses	O
to	O
extracellular	O
Wnt	O
signals	O
.	O
We	O
show	O
here	O
that	O
T	O
cell	O
maturation	O
depends	O
on	O
the	O
presence	O
of	O
the	O
beta-catenin	B-protein
--	I-protein
binding	I-protein
domain	I-protein
in	O
TCF-1	B-protein
.	O
This	O
domain	O
is	O
necessary	O
to	O
mediate	O
the	O
survival	O
of	O
immature	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
double-positive	O
(	O
DP	O
)	O
thymocytes	O
.	O
Accelerated	O
spontaneous	O
thymocyte	O
death	O
in	O
the	O
absence	O
of	O
TCF-1	B-protein
correlates	O
with	O
aberrantly	O
low	O
expression	O
of	O
the	O
anti-apoptotic	B-protein
protein	I-protein
Bcl-x	I-protein
(	O
L	O
)	O
.	O
Increasing	O
anti-apoptotic	B-protein
effectors	I-protein
in	O
thymocytes	O
by	O
the	O
use	O
of	O
a	O
Bcl-2	O
transgene	O
rescued	O
TCF-1-deficient	O
DP	O
thymocytes	O
from	O
apoptosis	O
.	O
Thus	O
,	O
TCF-1	B-protein
,	O
upon	O
association	O
with	O
beta-catenin	O
,	O
transiently	O
ensures	O
the	O
survival	O
of	O
immature	O
T	O
cells	O
,	O
which	O
enables	O
them	O
to	O
generate	O
and	O
edit	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	I-protein
alpha	I-protein
chains	I-protein
and	O
attempt	O
TCR	O
-mediated	O
positive	O
selection	O
.	O
TRAIL/Apo2L	O
ligand	O
selectively	O
induces	O
apoptosis	O
and	O
overcomes	O
drug	O
resistance	O
in	O
multiple	O
myeloma	O
:	O
therapeutic	O
applications	O
.	O
Multiple	O
myeloma	O
(	O
MM	O
)	O
remains	O
incurable	O
and	O
novel	O
treatments	O
are	O
urgently	O
needed	O
.	O
Preclinical	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluations	O
were	O
performed	O
to	O
assess	O
the	O
potential	O
therapeutic	O
applications	O
of	O
human	B-protein
recombinant	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
-related	O
apoptosis-inducing	O
ligand/Apo2	O
ligand	O
(	O
TRAIL/Apo2L	O
)	O
in	O
MM	O
.	O
TRAIL/Apo2L	O
potently	O
induced	O
apoptosis	O
of	O
MM	O
cells	O
from	O
patients	O
and	O
the	O
majority	O
of	O
MM	O
cell	O
lines	O
,	O
including	O
cells	O
sensitive	O
or	O
resistant	O
to	O
dexamethasone	O
(	O
Dex	O
)	O
,	O
doxorubicin	O
(	O
Dox	O
)	O
,	O
melphalan	O
,	O
and	O
mitoxantrone	O
.	O
TRAIL/Apo2L	O
also	O
overcame	O
the	O
survival	O
effect	O
of	O
interleukin	B-protein
6	I-protein
on	O
MM	O
cells	O
and	O
did	O
not	O
affect	O
the	O
survival	O
of	O
peripheral	O
blood	O
and	O
bone	O
marrow	O
mononuclear	O
cells	O
and	O
purified	O
B	O
cells	O
from	O
healthy	O
donors	O
.	O
The	O
status	O
of	O
the	O
TRAIL	O
receptors	O
(	O
assessed	O
by	O
immunoblotting	O
and	O
flow	O
cytometry	O
)	O
could	O
not	O
predict	O
TRAIL	O
sensitivity	O
of	O
MM	O
cells	O
.	O
The	O
anti-MM	O
activity	O
of	O
TRAIL/Apo2L	O
was	O
confirmed	O
in	O
nu/xid/bg	O
mice	O
xenografted	O
with	O
human	O
MM	O
cells	O
;	O
TRAIL	O
(	O
500	O
microg	O
intraperitoneally	O
daily	O
for	O
14	O
days	O
)	O
was	O
well	O
tolerated	O
and	O
significantly	O
suppressed	O
the	O
growth	O
of	O
plasmacytomas	O
.	O
Dox	O
up-regulated	O
the	O
expression	O
of	O
the	O
TRAIL	B-protein
receptor	I-protein
death	I-protein
receptor	I-protein
5	I-protein
(	O
DR5	O
)	O
and	O
synergistically	O
enhanced	O
the	O
effect	O
of	O
TRAIL	O
not	O
only	O
against	O
MM	O
cells	O
sensitive	O
to	O
,	O
but	O
also	O
against	O
those	O
resistant	O
to	O
,	O
Dex-	O
or	O
Dox-induced	O
apoptosis	O
.	O
Nuclear	B-protein
factor	I-protein
(	O
NF	O
)	O
-kappaB	O
inhibitors	O
,	O
such	O
as	O
SN50	O
(	O
a	O
cell-permeable	O
inhibitor	O
of	O
the	O
nuclear	O
translocation	O
and	O
transcriptional	O
activity	O
of	O
NF-kappaB	B-protein
)	O
or	O
the	O
proteasome	O
inhibitor	O
PS-341	O
,	O
enhanced	O
the	O
proapoptotic	O
activity	O
of	O
TRAIL/Apo2L	O
against	O
TRAIL-sensitive	O
MM	O
cells	O
,	O
whereas	O
SN50	O
reversed	O
the	O
TRAIL	O
resistance	O
of	O
ARH-77	B-protein
and	O
IM-9	O
MM	O
cells	O
.	O
Importantly	O
,	O
normal	O
B	O
lymphocytes	O
were	O
not	O
sensitized	O
to	O
TRAIL	O
by	O
either	O
Dox	O
,	O
SN50	O
,	O
or	O
PS-341	O
.	O
These	O
preclinical	O
studies	O
suggest	O
that	O
TRAIL/Apo2L	O
can	O
overcome	O
conventional	O
drug	O
resistance	O
and	O
provide	O
the	O
basis	O
for	O
clinical	O
trials	O
of	O
TRAIL	O
-based	O
treatment	O
regimens	O
to	O
improve	O
outcome	O
in	O
patients	O
with	O
MM	O
.	O
(	O
2001	O
;	O
98	O
:	O
795-804	O
)	O
CD28	O
costimulation	O
is	O
required	O
not	O
only	O
to	O
induce	O
IL-12	B-protein
receptor	I-protein
but	O
also	O
to	O
render	O
janus	O
kinases/STAT4	O
responsive	O
to	O
IL-12	B-protein
stimulation	O
in	O
TCR-triggered	O
T	O
cells	O
.	O
The	O
activation	O
of	O
resting	O
T	O
cells	O
for	O
the	O
acquisition	O
of	O
various	O
functions	O
depends	O
on	O
whether	O
CD28	O
costimulatory	O
signals	O
are	O
provided	O
upon	O
T	B-protein
cell	I-protein
receptor	I-protein
stimulation	O
.	O
Here	O
,	O
we	O
investigated	O
how	O
CD28	O
costimulation	O
functions	O
to	O
allow	O
TCR	O
-triggered	O
resting	O
T	O
cells	O
to	O
acquire	O
IL-12	O
responsiveness	O
.	O
When	O
T	O
cells	O
are	O
stimulated	O
with	O
low	O
doses	O
of	O
anti-CD3	B-protein
mAb	I-protein
,	O
CD28	O
costimulation	O
was	O
required	O
for	O
the	O
optimal	O
levels	O
of	O
IL-12	B-protein
receptor	I-protein
(	O
IL-12R	O
)	O
expression	O
.	O
However	O
,	O
stimulation	O
of	O
T	O
cells	O
with	O
high	O
doses	O
of	O
anti-CD3	O
alone	O
induced	O
comparable	O
levels	O
of	O
IL-12R	O
expression	O
to	O
those	O
induced	O
upon	O
CD28	O
costimulation	O
.	O
Nevertheless	O
,	O
there	O
was	O
a	O
substantial	O
difference	O
in	O
IL-12	O
responsiveness	O
between	O
these	O
two	O
groups	O
of	O
T	O
cells	O
:	O
compared	O
to	O
anti-CD28-costimulated	O
T	O
cells	O
,	O
T	O
cells	O
that	O
were	O
not	O
costimulated	O
with	O
anti-CD28	O
exhibited	O
decreased	O
levels	O
of	O
Janus	B-protein
kinases	I-protein
(	O
JAK	O
)	O
JAK2/TYK2	O
and	O
STAT4	O
phosphorylation	O
and	O
IFN-y	O
production	O
following	O
IL-12	O
stimulation	O
.	O
Importantly	O
,	O
STAT6	O
phosphorylation	O
following	O
IL-4	O
stimulation	O
was	O
not	O
decreased	O
in	O
anti-CD28-uncostimulated	O
T	O
cells	O
.	O
These	O
resutls	O
indicate	O
that	O
CD28	O
costimulation	O
not	O
only	O
contributes	O
to	O
up-regulating	O
IL-12R	O
expression	O
but	O
is	O
also	O
required	O
to	O
render	O
JAKs/STAT4	O
responsive	O
to	O
IL-12	O
stimulation	O
.	O
Constitutively	O
activated	O
Akt-1	O
is	O
vital	O
for	O
the	O
survival	O
of	O
human	O
monocyte-differentiated	O
macrophages	O
.	O
Role	O
of	O
Mcl-1	O
,	O
independent	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
,	O
Bad	O
,	O
or	O
caspase	O
activation	O
.	O
Recent	O
data	O
from	O
mice	O
deficient	O
for	O
phosphatase	O
and	O
tensin	O
homologue	O
deleted	O
from	O
chromosome	O
10	O
or	O
src	B-protein
homology	I-protein
2	I-protein
domain-containing	I-protein
5	I-protein
'	I-protein
inositol	I-protein
phosphatase	I-protein
,	O
phosphatases	O
that	O
negatively	O
regulate	O
the	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI3K	O
)	O
pathway	O
,	O
revealed	O
an	O
increased	O
number	O
of	O
macrophages	O
in	O
these	O
animals	O
,	O
suggesting	O
an	O
essential	O
role	O
for	O
the	O
PI3K	O
pathway	O
for	O
macro-phage	O
survival	O
.	O
Here	O
,	O
we	O
focused	O
on	O
the	O
role	O
of	O
the	O
PI3K-regulated	O
serine/threonine	O
kinase	O
Akt-1	O
in	O
modulating	O
macrophage	O
survival	O
.	O
Akt-1	O
was	O
constitutively	O
activated	O
in	O
human	O
macrophages	O
and	O
addition	O
of	O
the	O
PI3K	O
inhibitor	O
,	O
LY294002	O
,	O
suppressed	O
the	O
activation	O
of	O
Akt-1	O
and	O
induced	O
cell	O
death	O
.	O
Furthermore	O
,	O
suppression	O
of	O
Akt-1	O
by	O
inhibition	O
of	O
PI3K	B-protein
or	O
a	O
dominant	O
negative	O
(	O
DN	O
)	O
Akt-1	O
resulted	O
in	O
loss	O
of	O
mitochondrial	O
transmembrane	O
potential	O
,	O
activation	O
of	O
caspases-9	O
and	O
-3	O
,	O
and	O
DNA	O
fragmentation	O
.	O
The	O
effects	O
of	O
PI3K	O
inhibition	O
were	O
reversed	O
by	O
the	O
ectopic	O
expression	O
of	O
constitutively	O
activated	O
Akt-1	O
or	O
Bcl-x	O
(	O
L	O
)	O
.	O
Inhibition	O
of	O
PI3K	O
/Akt-1	O
pathway	O
either	O
by	O
LY294002	O
or	O
DN	O
Akt-1	O
had	O
no	O
effect	O
on	O
the	O
constitutive	O
or	O
inducible	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
in	O
human	O
macrophages	O
.	O
However	O
,	O
after	O
inhibition	O
of	O
the	O
PI3K	B-protein
/	O
Akt-1	B-protein
pathway	O
,	O
a	O
marked	O
decrease	O
in	O
the	O
expression	O
of	O
the	O
antiapoptotic	O
molecule	O
Mcl-1	O
,	O
but	O
not	O
other	O
Bcl-2	B-protein
family	I-protein
members	I-protein
was	O
observed	O
,	O
and	O
Mcl-1	O
rescued	O
macrophages	O
from	O
LY294002-induced	O
cell	O
death	O
.	O
Further	O
,	O
inhibition	O
of	O
Mcl-1	O
by	O
antisense	O
oligonucleotides	O
,	O
also	O
resulted	O
in	O
macrophage	O
apoptosis	O
.	O
Thus	O
,	O
our	O
findings	O
demonstrate	O
that	O
the	O
constitutive	O
activation	O
of	O
Akt-1	B-protein
regulates	O
macrophage	O
survival	O
through	O
Mcl-1	O
,	O
which	O
is	O
independent	O
of	O
caspases	O
,	O
NF-kappaB	B-protein
,	O
or	O
Bad	O
.	O
GRbeta	O
expression	O
in	O
nasal	O
polyp	O
inflammatory	O
cells	O
and	O
its	O
relationship	O
to	O
the	O
anti-inflammatory	O
effects	O
of	O
intranasal	O
fluticasone	O
.	O
BACKGROUND	O
:	O
Nasal	O
polyposis	O
disease	O
is	O
an	O
inflammatory	O
disorder	O
with	O
intense	O
eosinophilic	O
infiltration	O
of	O
respiratory	O
mucosa	O
that	O
is	O
often	O
difficult	O
to	O
control	O
with	O
topical	O
steroids	O
.	O
Recent	O
evidence	O
suggests	O
that	O
overexpression	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
splice	O
variant	O
GRbeta	O
in	O
inflammatory	O
cells	O
might	O
contribute	O
to	O
steroid	O
insensitivity	O
in	O
diseases	O
such	O
as	O
asthma	O
.	O
OBJECTIVE	O
:	O
The	O
purposes	O
of	O
this	O
investigation	O
were	O
to	O
determine	O
whether	O
nasal	O
polyp	O
(	O
NP	O
)	O
inflammatory	O
cells	O
overexpress	O
GRbeta	O
and	O
to	O
examine	O
whether	O
GRbeta	O
overexpression	O
is	O
associated	O
with	O
insensitivity	O
to	O
the	O
potent	O
topical	O
steroid	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
.	O
METHODS	O
:	O
Biopsies	O
were	O
obtained	O
from	O
10	O
subjects	O
with	O
NPs	O
before	O
and	O
4	O
weeks	O
after	O
treatment	O
with	O
intranasal	O
FP	O
.	O
Middle	O
turbinates	O
biopsies	O
from	O
6	O
healthy	O
,	O
nonallergic	O
subjects	O
served	O
as	O
normal	O
controls	O
.	O
Biopsies	O
were	O
immunostained	O
for	O
inflammatory	O
cell	O
markers	O
as	O
well	O
as	O
GRbeta	O
and	O
probed	O
for	O
various	O
cytokine	O
mRNA	O
.	O
The	O
anti-inflammatory	O
response	O
to	O
FP	O
was	O
examined	O
in	O
relation	O
to	O
pretreatment	O
levels	O
of	O
GRbeta	O
expression	O
.	O
RESULTS	O
:	O
The	O
total	O
numbers	O
of	O
inflammatory	O
cells	O
were	O
increased	O
in	O
NPs	O
.	O
The	O
percentage	O
of	O
inflammatory	O
cells	O
expressing	O
GRbeta	O
was	O
also	O
increased	O
(	O
40.5	O
%	O
+/-	O
19.2	O
%	O
vs	O
16.1	O
%	O
+/-	O
4.0	O
%	O
,	O
P	O
=.009	O
)	O
.	O
GRbeta	O
expression	O
in	O
NPs	O
was	O
almost	O
exclusive	O
to	O
T	O
lymphocytes	O
,	O
eosinophils	O
,	O
and	O
macrophages	O
.	O
An	O
inverse	O
correlation	O
was	O
observed	O
between	O
the	O
baseline	O
inflammatory	O
cell	O
GRbeta	O
expression	O
and	O
the	O
reduction	O
after	O
FP	O
treatment	O
in	O
EG2-positive	O
eosinophils	O
,	O
CD4-positive	O
T	O
lymphocytes	O
,	O
endothelial	O
VCAM-1	O
expression	O
,	O
and	O
IL-4	B-protein
mRNA-positive	O
cells	O
.	O
NPs	O
that	O
were	O
``	O
FP-insensitive	O
''	O
in	O
terms	O
of	O
suppression	O
of	O
eosinophil	O
numbers	O
(	O
major	O
basic	O
protein	O
-positive	O
)	O
had	O
a	O
significantly	O
greater	O
percentage	O
of	O
GRbeta-positive	O
inflammatory	O
cells	O
,	O
a	O
higher	O
ratio	O
of	O
GRbeta-positive/GRalpha-positive	O
cells	O
,	O
and	O
increased	O
numbers	O
of	O
GRbeta-positive	O
eosinophils	O
and	O
macrophages	O
in	O
comparison	O
with	O
those	O
that	O
were	O
``	O
''	O
``	O
FP-insensitive	O
''	O
NPs	O
also	O
demonstrated	O
a	O
higher	O
percentage	O
of	O
IL-5-positive	O
inflammatory	O
cells	O
expressing	O
GRbeta	O
before	O
and	O
after	O
FP	O
treatment	O
.	O
CONCLUSION	O
:	O
GRbeta	O
expression	O
appears	O
to	O
be	O
a	O
marker	O
of	O
steroid	O
insensitivity	O
in	O
NPs	O
.	O
Expression	O
of	O
GRbeta	O
by	O
NP	O
inflammatory	O
cells	O
,	O
particularly	O
T	O
cells	O
and	O
eosinophils	O
,	O
might	O
render	O
them	O
resistant	O
to	O
suppression	O
by	O
topical	O
steroids	O
and	O
thereby	O
contribute	O
to	O
persistent	O
NP	O
inflammation	O
.	O
Transcriptional	O
regulation	O
of	O
galectin-10	O
(	O
eosinophil	O
Charcot-Leyden	O
crystal	O
protein	O
)	O
:	O
a	O
GC	O
box	O
(	O
-44	O
to	O
-50	O
)	O
controls	O
butyric	O
acid	O
induction	O
of	O
gene	O
expression	O
.	O
Galectin-10	O
(	O
gal-10	O
,	O
also	O
known	O
as	O
Charcot-Leyden	B-protein
crystal	I-protein
protein	I-protein
)	O
is	O
a	O
member	O
of	O
the	O
galectin	B-protein
family	I-protein
of	I-protein
beta-galactoside	I-protein
binding	I-protein
proteins	I-protein
that	O
is	O
expressed	O
uniquely	O
in	O
eosinophilic	O
and	O
basophilic	O
leukocytes	O
.	O
To	O
gain	O
a	O
better	O
understanding	O
of	O
galectin	O
gene	O
expression	O
,	O
we	O
present	O
an	O
analysis	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gene	O
encoding	O
gal-10	O
.	O
Analysis	O
of	O
the	O
minimal	O
promoter	O
revealed	O
nine	O
consensus-binding	O
sites	O
for	O
transcription	B-protein
factors	I-protein
,	O
including	O
several	O
that	O
are	O
also	O
found	O
in	O
the	O
minimal	O
promoters	O
of	O
galectins	O
-1	O
,	O
-2	O
,	O
and	O
-3	O
.	O
The	O
decrease	O
in	O
gal-10	O
promoter	O
activity	O
after	O
disruption	O
of	O
either	O
the	O
GC	O
box	O
(	O
-44	O
to	O
-50	O
)	O
or	O
the	O
Oct	O
site	O
(	O
-255	O
to	O
-261	O
)	O
suggests	O
that	O
these	O
sites	O
,	O
along	O
with	O
the	O
previously	O
characterized	O
GATA	O
and	O
EoTF	O
sites	O
,	O
are	O
necessary	O
for	O
full	O
promoter	O
activity	O
.	O
By	O
supershift	O
analysis	O
,	O
we	O
demonstrate	O
binding	O
of	O
the	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
Oct1	O
to	O
the	O
consensus	O
GC	O
box	O
and	O
the	O
Oct	O
site	O
,	O
respectively	O
.	O
Similar	O
to	O
gal-1	O
,	O
gal-10	O
expression	O
is	O
induced	O
by	O
butyric	O
acid	O
,	O
an	O
effect	O
that	O
is	O
lost	O
upon	O
ablation	O
of	O
the	O
GC	O
box	O
.	O
Additionally	O
,	O
we	O
demonstrate	O
AML3	O
binding	O
to	O
the	O
consensus	O
AML	O
site	O
and	O
YY1	O
binding	O
to	O
the	O
Inr	O
sequence	O
,	O
both	O
elements	O
functioning	O
as	O
silencers	O
in	O
the	O
gal-10	O
promoter	O
.	O
Tumour-stromal	O
interactions	O
.	O
Role	O
of	O
the	O
stroma	O
in	O
mammary	O
development	O
.	O
Mammary	O
development	O
depends	O
on	O
branching	O
morphogenesis	O
,	O
namely	O
the	O
bifurcation	O
and	O
extension	O
of	O
ductal	O
growth	O
points	O
(	O
end	O
buds	O
)	O
and	O
secretory	O
lobules	O
into	O
a	O
more	O
or	O
less	O
fatty	O
stroma	O
.	O
Because	O
breast	O
carcinomas	O
are	O
overwhelmingly	O
ductal	O
in	O
origin	O
,	O
this	O
review	O
focuses	O
on	O
stromal	O
influences	O
guiding	O
postnatal	O
ductal	O
development	O
and	O
there	O
is	O
only	O
the	O
briefest	O
account	O
of	O
the	O
role	O
of	O
embryonic	O
stroma	O
(	O
mesenchyme	O
)	O
.	O
The	O
stroma	O
as	O
the	O
necessary	O
target	O
for	O
endocrine	O
mammogens	O
and	O
the	O
source	O
of	O
stimulatory	B-protein
growth	I-protein
factors	I-protein
is	O
described	O
and	O
the	O
importance	O
of	O
mammary	O
epithelium-induced	O
modifications	O
of	O
the	O
periductal	O
stroma	O
is	O
emphasized	O
.	O
Evidence	O
is	O
presented	O
that	O
if	O
they	O
are	O
to	O
grow	O
,	O
end	O
buds	O
must	O
condition	O
proximal	O
fatty	O
stroma	O
by	O
recruiting	O
white	O
blood	O
cells	O
as	O
well	O
as	O
inducing	O
stromal	O
cell	O
division	O
and	O
,	O
possibly	O
,	O
estrogen	B-protein
receptors	I-protein
.	O
The	O
induction	O
of	O
a	O
fibrous	O
stromal	O
tunic	O
around	O
the	O
end	O
bud	O
is	O
described	O
and	O
its	O
likely	O
role	O
as	O
a	O
complex	O
ductal	O
morphogen	O
is	O
discussed	O
;	O
a	O
possible	O
role	O
in	O
growth	O
inhibition	O
is	O
also	O
considered	O
.	O
Although	O
the	O
signals	O
governing	O
fibrotic	O
induction	O
,	O
ductal	O
morphogenesis	O
,	O
and	O
growth	O
inhibition	O
are	O
unknown	O
,	O
a	O
role	O
for	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
is	O
highly	O
likely	O
and	O
is	O
discussed	O
.	O
Finally	O
,	O
a	O
need	O
for	O
new	O
conceptual	O
and	O
experimental	O
approaches	O
to	O
understanding	O
stromal-epithelial	O
signaling	O
is	O
discussed	O
.	O
Adipophilin	O
is	O
a	O
sensitive	O
marker	O
for	O
lipid	O
loading	O
in	O
human	O
blood	O
monocytes	O
.	O
Adipophilin	O
,	O
a	O
marker	O
of	O
lipid	O
accumulation	O
initially	O
described	O
in	O
adipocytes	O
,	O
was	O
recently	O
shown	O
to	O
be	O
induced	O
in	O
macrophage	O
foam	O
cells	O
.	O
We	O
found	O
that	O
even	O
freshly	O
isolated	O
blood	O
monocytes	O
express	O
adipophilin	O
and	O
that	O
the	O
amount	O
of	O
adipophilin	B-protein
protein	I-protein
is	O
variable	O
in	O
monocytes	O
from	O
different	O
healthy	O
individuals	O
.	O
However	O
,	O
the	O
physiological	O
expression	O
of	O
adipophilin	O
does	O
not	O
correlate	O
with	O
the	O
levels	O
of	O
free	O
fatty	O
acids	O
,	O
cholesterylesters	O
or	O
free	O
cholesterol	O
.	O
Enzymatically	O
modified	O
low-density	O
lipoprotein	O
(	O
E-LDL	O
)	O
induces	O
rapid	O
foam	O
cell	O
formation	O
in	O
monocytes	O
and	O
upregulates	O
adipophilin	O
mRNA	O
and	O
protein	O
within	O
2	O
h	O
of	O
incubation	O
.	O
This	O
rapid	O
induction	O
of	O
adipophilin	O
is	O
accompanied	O
by	O
a	O
significant	O
increase	O
of	O
free	O
fatty	O
acids	O
in	O
monocytes	O
incubated	O
with	O
E-LDL	O
.	O
Adipophilin	O
facilitates	O
the	O
uptake	O
of	O
free	O
fatty	O
acids	O
,	O
and	O
here	O
we	O
demonstrate	O
that	O
free	O
fatty	O
acids	O
increase	O
is	O
related	O
to	O
the	O
early	O
upregulation	O
of	O
adipophilin	O
expression	O
in	O
blood	O
monocytes	O
.	O
Fatty	O
acids	O
are	O
ligands	O
for	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor-gamma	I-protein
(	I-protein
PPARgamma	I-protein
)	O
,	O
and	O
the	O
upregulation	O
of	O
adipophilin	O
mRNA	O
by	O
PPARgamma	O
agonists	O
like	O
15d-PGJ	O
(	O
2	O
)	O
and	O
ciglitazone	O
indicates	O
that	O
PPARgamma	B-protein
may	O
mediate	O
the	O
induction	O
of	O
adipophilin	O
expression	O
in	O
human	O
blood	O
monocytes	O
.	O
Constitutive	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
melanoma	O
cell	O
lines	O
results	O
from	O
the	O
transcription	O
of	O
class	O
II	O
transactivator	O
abnormally	O
initiated	O
from	O
its	O
B	O
cell-specific	O
promoter	O
.	O
In	O
melanoma	O
cell	O
lines	O
,	O
two	O
different	O
patterns	O
of	O
MHC	O
class	O
II	O
expression	O
have	O
been	O
described	O
,	O
either	O
an	O
IFN	O
gamma-inducible	O
expression	O
of	O
HLA-DR	B-protein
and	O
HLA-DP	O
,	O
with	O
a	O
faint	O
or	O
null	O
expression	O
of	O
HLA-DQ	B-protein
,	O
resembling	O
that	O
described	O
for	O
melanocytes	O
,	O
or	O
a	O
constitutive	O
expression	O
,	O
,	O
IFN-gamma	B-protein
independent	O
,	O
of	O
all	O
three	O
HLA-D	O
isotypes	O
.	O
As	O
this	O
latter	O
phenotype	O
has	O
been	O
associated	O
with	O
a	O
more	O
rapid	O
progression	O
of	O
melanoma	O
tumors	O
,	O
we	O
have	O
analyzed	O
in	O
different	O
melanoma	O
cell	O
lines	O
the	O
molecular	O
mechanisms	O
leading	O
to	O
this	O
abnormal	O
pattern	O
of	O
MHC	O
class	O
II	O
expression	O
.	O
In	O
agreement	O
with	O
the	O
evidence	O
of	O
a	O
coordinate	O
transcription	O
of	O
the	O
HLA-D	O
genes	O
in	O
these	O
cell	O
lines	O
,	O
we	O
have	O
shown	O
the	O
constitutive	O
expression	O
of	O
CIITA	O
(	O
class	O
II	O
transactivator	O
)	O
transcripts	O
,	O
CIITA	O
being	O
known	O
as	O
the	O
master	O
switch	O
of	O
MHC	O
class	O
II	O
expression	O
.	O
Unexpectedly	O
,	O
these	O
transcripts	O
initiate	O
from	O
promoter	O
III	O
of	O
the	O
CIITA	O
gene	O
,	O
a	O
promoter	O
that	O
is	O
mainly	O
used	O
constitutively	O
in	O
B	O
lymphocytes	O
.	O
This	O
expression	O
was	O
further	O
shown	O
to	O
occur	O
through	O
factor	O
(	O
s	O
)	O
acting	O
on	O
the	O
enhancer	O
located	O
upstream	O
of	O
CIITA	O
promoter	O
III	O
,	O
which	O
was	O
previously	O
described	O
in	O
epithelioid	O
cells	O
as	O
an	O
IFN-gamma-response	O
sequence	O
.	O
The	O
hypothesis	O
of	O
a	O
general	O
abnormality	O
of	O
the	O
IFN-gamma	O
transduction	O
pathway	O
was	O
dismissed	O
.	O
Constitutive	O
transcription	O
of	O
CIITA	O
from	O
promoter	O
III	O
having	O
been	O
observed	O
in	O
unrelated	O
melanoma	O
cell	O
lines	O
,	O
we	O
propose	O
the	O
hypothesis	O
that	O
this	O
phenomenon	O
might	O
not	O
be	O
a	O
random	O
event	O
,	O
but	O
could	O
be	O
linked	O
to	O
the	O
neoplasic	O
state	O
of	O
the	O
melanoma	O
cells	O
Caspase	O
-mediated	O
calcineurin	O
activation	O
contributes	O
to	O
IL-2	B-protein
release	O
during	O
T	O
cell	O
activation	O
.	O
Calcineurin	B-protein
,	O
a	O
Ca	O
(	O
2+	O
)	O
/calmodulin-dependent	O
Ser/Thr	B-protein
phosphatase	I-protein
(	I-protein
protein	I-protein
phosphatase	I-protein
2B	I-protein
)	O
,	O
plays	O
a	O
critical	O
role	O
in	O
IL-2	O
production	O
during	O
T	O
cell	O
activation	O
.	O
It	O
has	O
been	O
previously	O
reported	O
that	O
IL-2	B-protein
release	O
in	O
activated	O
Jurkat	O
T	O
requires	O
caspase-like	O
activity	O
(	O
Posmantur	O
et	O
(	O
1998	O
)	O
244	O
,	O
302-309	O
)	O
.	O
We	O
report	O
here	O
that	O
the	O
60-kDa	B-protein
catalytic	I-protein
subunit	I-protein
of	O
calcineurin	B-protein
A	I-protein
(	I-protein
Cn	I-protein
A	I-protein
)	O
was	O
partially	O
cleaved	O
to	O
a	O
45-kDa	O
form	O
in	O
phytohemagglutinin	B-protein
A	I-protein
(	I-protein
PHA	I-protein
)	O
or	O
phorbol	O
ester	O
+	O
ionomycin	O
(	O
P	B-protein
+	I-protein
I	I-protein
)	O
-activated	O
Jurkat	O
cells	O
.	O
In	O
parallel	O
,	O
proteolytic	O
activation	O
of	O
upstream	O
caspases	O
(	O
caspase-8	O
and	O
-9	O
)	O
as	O
well	O
as	O
effector	O
caspase-3	O
was	O
also	O
observed	O
.	O
Cn	O
A	O
cleavage	O
was	O
caspase	O
mediated	O
,	O
since	O
it	O
was	O
inhibitable	O
by	O
pan-caspase	O
inhibitor	O
Cbz-Asp-CH	O
(	O
2	O
)	O
OC	O
(	O
O	O
)	O
-2	O
,	O
6-dichlorobenzene	O
(	O
Z-D-DCB	O
)	O
.	O
Cn	O
A	O
cleavage	O
was	O
also	O
observed	O
when	O
purified	O
calcineurin	O
was	O
digested	O
in	O
vitro	O
with	O
caspase-3	O
.	O
Truncated	O
Cn	O
A	O
was	O
associated	O
with	O
enhanced	O
phosphatase	O
activity	O
and	O
reduced	O
calmodulin	O
sensitivity	O
.	O
Furthermore	O
,	O
in	O
PHA	O
or	O
P	B-protein
+	O
I-activated	O
Jurkat	O
cells	O
,	O
dephosphorylation	O
of	O
calcineurin	B-protein
substrate	I-protein
NFATc	I-protein
(	O
a	O
transcription	B-protein
factor	I-protein
known	O
to	O
be	O
involved	O
in	O
transactivation	O
of	O
the	O
IL-2	O
gene	O
)	O
,	O
was	O
also	O
suppressed	O
by	O
Z-D-DCB	O
.	O
Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
caspase-mediated	O
cleavage	O
of	O
Cn	O
A	O
contributes	O
to	O
IL-2	O
production	O
during	O
T	O
cell	O
activation	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
Maturation	O
of	O
human	O
dendritic	O
cells	O
as	O
sulfasalazine	O
target	O
.	O
AIM	O
:	O
Sulfasalazine	O
,	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
,	O
is	O
effective	O
in	O
treating	O
some	O
autoimmune	O
diseases	O
,	O
but	O
its	O
mechanism	O
of	O
action	O
is	O
unclear	O
.	O
To	O
determine	O
whether	O
dendritic	O
cells	O
could	O
be	O
a	O
possible	O
target	O
of	O
the	O
drug	O
,	O
we	O
studied	O
the	O
effects	O
of	O
sulfasalazine	O
and	O
its	O
metabolites	O
,	O
aminosalicylate	O
and	O
sulfapyridine	O
,	O
on	O
in	O
vitro	O
maturation	O
(	O
terminal	O
differentiation	O
)	O
of	O
human	O
myeloid	O
dendritic	O
cells	O
.	O
METHODS	O
:	O
We	O
prepared	O
immature	O
dendritic	O
cells	O
by	O
incubating	O
CD14-positive	O
cells	O
in	O
the	O
presence	O
of	O
granulocyte-	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
.	O
The	O
cells	O
were	O
matured	O
by	O
addition	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
-a	O
,	O
IL-1	B-protein
beta	I-protein
,	O
and	O
prostaglandin	O
E2	O
in	O
the	O
presence	O
of	O
sulfasalazine	O
or	O
its	O
metabolites	O
--	O
aminosalicylate	O
and	O
sulfapyridine	O
,	O
or	O
their	O
combinations	O
.	O
We	O
quantified	O
the	O
effect	O
of	O
drugs	O
on	O
the	O
dendritic	O
cell	O
characteristics	O
,	O
such	O
as	O
stimulation	O
of	O
autologous	O
and	O
allogeneic	O
pan-T	O
cell	O
proliferation	O
,	O
surface	O
marker	O
phenotype	O
,	O
IL-12	B-protein
p40	I-protein
subunit	I-protein
secretion	I-protein
,	O
and	O
activation	O
of	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
.	O
RESULTS	O
:	O
Dendritic	O
cells	O
treated	O
with	O
sulfasalazine	O
(	O
1.25	O
micromol/L	O
or	O
2.5	O
micromol/L	O
)	O
could	O
not	O
stimulate	O
T	O
cells	O
(	O
p	O
<	O
0.028	O
,	O
two-sided	O
paired	O
t-test	O
)	O
.	O
In	O
distinction	O
to	O
drug-free	O
maturing	O
dendritic	O
cells	O
,	O
2.5	O
micromol/L	O
sulfasalazine	O
upregulated	O
the	O
levels	O
of	O
CD14	B-protein
and	O
CD68	B-protein
and	O
downregulated	O
the	O
levels	O
of	O
CD40	B-protein
,	O
CD80	B-protein
,	O
and	O
CD83	O
(	O
for	O
all	O
CD	O
markers	O
,	O
p	O
<	O
0.03	O
for	O
difference	O
between	O
measurements	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
sulfasalazine	O
)	O
.	O
From	O
concentration-dependent	O
changes	O
in	O
CD83	O
expression	O
,	O
we	O
found	O
an	O
apparent	O
ID50	O
>	O
>	O
1.5	O
micromol/L	O
sulfasalazine	O
.	O
The	O
apparent	O
ID50	O
value	O
for	O
aminosalicylate-inhibited	O
maturation	O
was	O
4	O
micromol/L	O
.	O
Sulfapyridine	O
had	O
no	O
effect	O
.	O
At	O
1.25	O
micromol/L	O
,	O
sulfasalazine	O
largely	O
inhibited	O
NF-kB	O
activation	O
in	O
dendritic	O
cells	O
.	O
CONCLUSION	O
:	O
Maturing	O
human	O
dendritic	O
cells	O
are	O
hundred-fold	O
more	O
sensitive	O
to	O
sulfasalazine	O
than	O
T	O
cells	O
and	O
NK	O
cells	O
and	O
the	O
most	O
sensitive	O
human	O
cells	O
described	O
so	O
far	O
.	O
Thus	O
,	O
dendritic	O
cell	O
maturation	O
is	O
an	O
important	O
target	O
of	O
sulfasalazine	O
.	O
Because	O
of	O
the	O
role	O
of	O
dendritic	O
cells	O
in	O
(	O
auto	O
)	O
immunity	O
,	O
inhibition	O
of	O
their	O
maturation	O
might	O
provide	O
a	O
target	O
for	O
further	O
optimization	O
of	O
sulfasalazine	O
therapy	O
.	O
Defective	O
function	O
of	O
the	O
proteasome	O
in	O
autoimmunity	O
:	O
involvement	O
of	O
impaired	O
NF-kappaB	O
activation	O
.	O
Type	O
1	O
diabetes	O
(	O
also	O
known	O
as	O
insulin-dependent	O
diabetes	O
mellitus	O
or	O
juvenile-onset	O
diabetes	O
)	O
is	O
usually	O
caused	O
by	O
T	O
cell-mediated	O
autoimmunity	O
,	O
with	O
a	O
prediabetic	O
state	O
characterized	O
by	O
the	O
production	O
of	O
autoantibodies	O
specific	O
for	O
proteins	O
expressed	O
by	O
pancreatic	O
beta	O
cells	O
.	O
The	O
nonobese	O
patient	O
with	O
diabetes	O
(	O
NOD	O
)	O
mouse	O
is	O
a	O
spontaneous	O
model	O
of	O
type	O
1	O
diabetes	O
with	O
a	O
strong	O
genetic	O
component	O
that	O
maps	O
to	O
the	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	O
MHC	O
)	O
region	O
of	O
the	O
genome	O
.	O
A	O
specific	O
proteasome	O
defect	O
has	O
been	O
identified	O
in	O
NOD	O
mouse	O
in	O
select	O
lymphocytic	O
and	O
monocytic	O
lineages	O
that	O
results	O
from	O
down-regulation	O
of	O
expression	O
of	O
the	O
proteasome	B-protein
subunit	I-protein
LMP2	I-protein
,	O
which	O
is	O
encoded	O
by	O
a	O
gene	O
in	O
the	O
MHC	O
genomic	O
region	O
.	O
This	O
defect	O
prevents	O
the	O
proteolytic	O
processing	O
required	O
for	O
the	O
production	O
and	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
which	O
plays	O
important	O
roles	O
in	O
immune	O
and	O
inflammatory	O
responses	O
,	O
as	O
well	O
as	O
increases	O
the	O
susceptibility	O
of	O
the	O
affected	O
cells	O
to	O
apoptosis	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O
The	O
novel	O
role	O
of	O
the	O
proteasome	O
in	O
dysfunction	O
in	O
autoimmunity	O
is	O
presented	O
and	O
documented	O
to	O
be	O
both	O
tissue	O
and	O
developmental	O
stage	O
specific	O
.	O
We	O
propose	O
a	O
role	O
of	O
the	O
proteasome	B-protein
as	O
a	O
step	O
in	O
disease	O
pathogenesis	O
and	O
tissue	O
targeting	O
.	O
Down-regulation	O
of	O
TDT	B-protein
transcription	O
in	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocytes	O
by	O
Ikaros	B-protein
proteins	I-protein
in	O
direct	O
competition	O
with	O
an	O
Ets	B-protein
activator	I-protein
.	O
Ikaros	B-protein
is	O
a	O
unique	O
regulator	O
of	O
lymphopoiesis	O
that	O
associates	O
with	O
pericentromeric	O
heterochromatin	O
and	O
has	O
been	O
implicated	O
in	O
heritable	O
gene	O
inactivation	O
.	O
Binding	O
and	O
competition	O
experiments	O
demonstrate	O
that	O
Ikaros	B-protein
dimers	I-protein
compete	O
with	O
an	O
Ets	O
activator	O
for	O
occupancy	O
of	O
the	O
lymphocyte-specific	O
TdT	O
promoter	O
.	O
Mutations	O
that	O
selectively	O
disrupt	O
Ikaros	B-protein
binding	O
to	O
an	O
integrated	O
TdT	O
promoter	O
had	O
no	O
effect	O
on	O
promoter	O
function	O
in	O
a	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocyte	O
line	O
.	O
However	O
,	O
these	O
mutations	O
abolished	O
down-regulation	O
on	O
differentiation	O
,	O
providing	O
evidence	O
that	O
Ikaros	B-protein
plays	O
a	O
direct	O
role	O
in	O
repression	O
.	O
Reduced	O
access	O
to	O
restriction	B-protein
enzyme	I-protein
cleavage	I-protein
suggested	O
that	O
chromatin	O
alterations	O
accompany	O
down-regulation	O
.	O
The	O
Ikaros-dependent	O
down-regulation	O
event	O
and	O
the	O
observed	O
chromatin	O
alterations	O
appear	O
to	O
precede	O
pericentromeric	O
repositioning	O
.	O
Current	O
models	O
propose	O
that	O
the	O
functions	O
of	O
Ikaros	B-protein
should	O
be	O
disrupted	O
by	O
a	O
small	O
isoform	O
that	O
retains	O
the	O
dimerization	O
domain	O
and	O
lacks	O
the	O
DNA-binding	B-protein
domain	I-protein
.	O
Surprisingly	O
,	O
in	O
the	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocyte	O
line	O
,	O
overexpression	O
of	O
a	O
small	O
Ikaros	O
isoform	O
had	O
no	O
effect	O
on	O
differentiation	O
or	O
on	O
the	O
pericentromeric	O
targeting	O
and	O
DNA-binding	O
properties	O
of	O
Ikaros	B-protein
.	O
Rather	O
,	O
the	O
small	O
isoform	O
assembled	O
into	O
multimeric	O
complexes	O
with	O
DNA-bound	O
Ikaros	B-protein
at	O
the	O
pericentromeric	O
foci	O
.	O
The	O
capacity	O
for	O
in	O
vivo	O
multimer	O
formation	O
suggests	O
that	O
interactions	O
between	O
Ikaros	B-protein
dimers	I-protein
bound	O
to	O
the	O
TdT	O
promoter	O
and	O
those	O
bound	O
to	O
pericentromeric	O
repeat	O
sequences	O
may	O
contribute	O
to	O
the	O
pericentromeric	O
repositioning	O
of	O
the	O
inactive	O
gene	O
.	O
Type	O
I	O
interferons	O
and	O
IL-12	O
:	O
convergence	O
and	O
cross-regulation	O
among	O
mediators	O
of	O
cellular	O
immunity	O
.	O
Therapeutic	O
use	O
of	O
type	B-protein
I	I-protein
IFN	I-protein
(	I-protein
IFN-alpha/beta	I-protein
)	O
has	O
become	O
common	O
.	O
Many	O
of	O
the	O
diverse	O
diseases	O
targeted	O
are	O
marked	O
by	O
pathogenetic	O
abnormalities	O
in	O
cell-mediated	O
immunity	O
(	O
CMI	O
)	O
,	O
these	O
cellular	O
immune	O
responses	O
either	O
causing	O
injury	O
to	O
the	O
host	O
,	O
lacking	O
sufficient	O
vigor	O
for	O
virus	O
or	O
tumor	O
clearance	O
,	O
or	O
both	O
.	O
In	O
general	O
,	O
therapeutic	O
efficacy	O
is	O
limited	O
.	O
It	O
is	O
thus	O
notable	O
that	O
the	O
pleiotropic	O
effects	O
of	O
type	O
I	O
IFN	O
on	O
CMI	O
remain	O
poorly	O
understood	O
.	O
We	O
characterized	O
the	O
effects	O
of	O
type	O
I	O
IFN	O
on	O
the	O
production	O
of	O
IL-12	B-protein
,	O
the	O
central	O
immunoregulatory	O
cytokine	O
of	O
the	O
CD4	O
(	O
+	O
)	O
T	O
cell	O
arm	O
of	O
CMI	O
.	O
We	O
show	O
that	O
type	O
I	O
IFN	O
are	O
potent	O
inhibitors	O
of	O
IL-12	B-protein
production	O
by	O
human	O
monocytes/macrophages	O
.	O
The	O
underlying	O
mechanism	O
involves	O
transcriptional	O
inhibition	O
of	O
the	O
IL-12p40	O
gene	O
,	O
marked	O
by	O
down-regulation	O
of	O
PU.1	B-protein
binding	O
activity	O
at	O
the	O
upstream	O
Ets	O
site	O
of	O
the	O
IL-12p40	O
promoter	O
.	O
Type	O
I	O
IFN	O
have	O
previously	O
been	O
shown	O
to	O
be	O
able	O
to	O
substitute	O
for	O
IL-12	B-protein
in	O
driving	O
IFN-gamma	O
production	O
from	O
T	O
and	O
NK	O
cells	O
.	O
The	O
ability	O
of	O
IFN-alpha/beta	B-protein
to	O
suppress	O
IL-12	O
production	O
while	O
up-regulating	O
IFN-gamma	O
production	O
suggests	O
a	O
possible	O
mechanistic	O
basis	O
for	O
the	O
difficulties	O
of	O
employing	O
these	O
cytokines	B-protein
in	O
diseases	O
involving	O
abnormalities	O
of	O
CMI	O
.	O
Nuclear	B-protein
factor-kappaB	I-protein
suppressive	O
and	O
inhibitor-kappaB	O
stimulatory	O
effects	O
of	O
troglitazone	O
in	O
obese	O
patients	O
with	O
type	O
2	O
diabetes	O
:	O
evidence	O
of	O
an	O
antiinflammatory	O
action	O
?	O
It	O
has	O
been	O
shown	O
recently	O
that	O
troglitazone	O
exerts	O
an	O
anti-inflammatory	O
effect	O
,	O
in	O
vitro	O
,	O
and	O
in	O
experimental	O
animals	O
.	O
To	O
test	O
these	O
properties	O
in	O
humans	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
troglitazone	O
on	O
the	O
proinflammatory	B-protein
transcription	I-protein
factor	I-protein
nuclear	B-protein
factor-kappaB	I-protein
and	O
its	O
inhibitory	B-protein
protein	I-protein
IkappaB	I-protein
in	O
mononuclear	O
cells	O
(	O
MNC	O
)	O
and	O
plasma	O
soluble	O
intracellular	B-protein
adhesion	I-protein
molecule-1	I-protein
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
,	O
plasminogen	B-protein
activator	I-protein
inhibitor-1	I-protein
,	O
and	O
C-reactive	B-protein
protein	I-protein
.	O
We	O
also	O
examined	O
the	O
effect	O
of	O
troglitazone	O
on	O
reactive	O
oxygen	O
species	O
generation	O
,	O
p47	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
expression	O
,	O
9-hydroxyoctadecadienoic	O
acid	O
(	O
9-HODE	O
)	O
,	O
13-HODE	O
,	O
o-tyrosine	O
,	O
and	O
m-tyrosine	O
in	O
obese	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O
Seven	O
obese	O
patients	O
with	O
type	O
2	O
diabetes	O
were	O
treated	O
with	O
troglitazone	O
(	O
400	O
mg/day	O
)	O
for	O
4	O
weeks	O
.	O
Blood	O
samples	O
were	O
obtained	O
at	O
weekly	O
intervals	O
.	O
Nuclear	B-protein
factor-kappaB	I-protein
binding	O
activity	O
in	O
MNC	O
nuclear	O
extracts	O
was	O
significantly	O
inhibited	O
after	O
troglitazone	O
treatment	O
at	O
week	O
1	O
and	O
continued	O
to	O
be	O
inhibited	O
up	O
to	O
week	O
4	O
.	O
On	O
the	O
other	O
hand	O
,	O
IkappaB	B-protein
protein	I-protein
levels	O
increased	O
significantly	O
after	O
troglitazone	O
treatment	O
at	O
week	O
1	O
,	O
and	O
this	O
increase	O
persisted	O
throughout	O
the	O
study	O
.	O
Plasma	B-protein
monocyte	I-protein
chemoattractant	I-protein
protein-1	I-protein
and	O
soluble	B-protein
intracellular	I-protein
adhesion	I-protein
molecule-1	I-protein
concentrations	O
did	O
not	O
decrease	O
significantly	O
after	O
troglitazone	O
treatment	O
,	O
although	O
there	O
was	O
a	O
trend	O
toward	O
inhibition	O
.	O
Reactive	O
oxygen	O
species	O
generation	O
by	O
polymorphonuclear	O
cells	O
and	O
MNC	O
,	O
p47	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
protein	I-protein
quantities	I-protein
,	O
plasminogen	B-protein
activator	I-protein
inhibitor-1	I-protein
,	O
and	O
C-reactive	O
protein	O
levels	O
decreased	O
significantly	O
after	O
troglitazone	O
intake	O
.	O
13-HODE/linoleic	O
acid	O
and	O
9-HODE/linoleic	O
acid	O
ratios	O
also	O
decreased	O
after	O
troglitazone	O
intake	O
.	O
However	O
,	O
o-tyrosine/phenylalanine	O
and	O
m-tyrosine/phenylalanine	O
ratios	O
did	O
not	O
change	O
significantly	O
.	O
These	O
data	O
show	O
that	O
troglitazone	O
has	O
profound	O
antiinflammatory	O
effects	O
in	O
addition	O
to	O
antioxidant	O
effects	O
in	O
obese	O
type	O
2	O
diabetics	O
;	O
these	O
effects	O
may	O
be	O
relevant	O
to	O
the	O
recently	O
described	O
beneficial	O
antiatherosclerotic	O
effects	O
of	O
troglitazone	O
at	O
the	O
vascular	O
level	O
.	O
OX40	O
stimulation	O
by	O
gp34/OX40	O
ligand	O
enhances	O
productive	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
.	O
OX40	O
is	O
a	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	I-protein
receptor	I-protein
superfamily	O
and	O
known	O
to	O
be	O
an	O
important	O
costimulatory	B-protein
molecule	I-protein
expressed	I-protein
on	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O
To	O
investigate	O
the	O
role	O
of	O
costimulation	O
of	O
OX40	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
by	O
its	O
natural	O
ligand	O
,	O
gp34	B-protein
,	O
the	O
OX40-transfected	O
ACH-2	O
cell	O
line	O
,	O
ACH-2/OX40	O
,	O
chronically	O
infected	O
with	O
HIV-1	O
,	O
was	O
cocultured	O
with	O
paraformaldehyde	O
(	O
PFA	O
)	O
-fixed	O
gp34-transfected	O
mouse	O
cell	O
line	O
,	O
SV-T2/gp34	O
.	O
The	O
results	O
showed	O
that	O
HIV-1	O
production	O
was	O
strongly	O
induced	O
.	O
This	O
was	O
followed	O
by	O
apparent	O
apoptosis	O
,	O
and	O
both	O
processes	O
were	O
specifically	O
inhibited	O
by	O
the	O
gp34	B-protein
-specific	I-protein
neutralizing	I-protein
monoclonal	I-protein
antibody	I-protein
5A8	I-protein
.	O
Endogenous	O
TNF	B-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
TNF-beta	O
production	O
were	O
not	O
involved	O
in	O
the	O
enhanced	O
HIV-1	O
production	O
.	O
Furthermore	O
,	O
enhanced	O
HIV-1	O
transcription	O
in	O
gp34	B-protein
-stimulated	O
ACH-2/OX40	O
cells	O
was	O
dependent	O
on	O
the	O
kappa	O
B	O
site	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
,	O
and	O
the	O
OX40-gp34	O
interaction	O
activated	O
NF-kappa	B-protein
B	I-protein
consisting	O
of	O
p50	B-protein
and	I-protein
p65	I-protein
subunits	I-protein
.	O
When	O
primary	O
activated	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
acutely	O
infected	O
with	O
HIV-1	O
(	O
NL4-3	O
)	O
(	O
CXCR4-using	O
T-cell-line-tropic	O
)	O
were	O
cocultured	O
with	O
PFA-fixed	O
gp34	O
(	O
+	O
)	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1-bearing	O
MT-2	O
cells	O
or	O
SV-T2/gp34	O
cells	O
,	O
HIV-1	O
production	O
was	O
also	O
markedly	O
enhanced	O
.	O
The	O
enhancement	O
was	O
again	O
significantly	O
inhibited	O
by	O
5A8	O
.	O
The	O
present	O
study	O
first	O
shows	O
that	O
OX40-gp34	O
interaction	O
stimulates	O
HIV-1	O
expression	O
and	O
suggests	O
that	O
OX40	O
triggering	O
by	O
gp34	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
enhancing	O
HIV-1	O
production	O
in	O
both	O
acutely	O
and	O
latently	O
infected	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
in	O
vivo	O
.	O
Troglitazone	O
,	O
a	O
PPARgamma	B-protein
ligand	I-protein
,	O
inhibits	O
osteopontin	O
gene	O
expression	O
in	O
human	O
monocytes/macrophage	O
THP-1	O
cells	O
.	O
Peroxizome	O
proliferator-activated	O
receptor-gamma	O
(	O
PPARgamma	B-protein
)	O
is	O
a	O
member	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
that	O
regulate	O
adipocyte	O
differentiation	O
.	O
Recent	O
studies	O
indicate	O
that	O
liganded	O
PPARgamma	O
not	O
only	O
promotes	O
differentiation	O
but	O
also	O
inhibits	O
the	O
activation	O
of	O
macrophages	O
.	O
Osteopontin	B-protein
,	O
a	O
component	O
of	O
extracellular	O
matrix	O
,	O
is	O
synthesized	O
by	O
macrophages	O
in	O
atherosclerotic	O
plaques	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
PPARgamma	B-protein
ligand	I-protein
regulates	O
osteopontin	O
gene	O
expression	O
in	O
THP-1	O
cells	O
,	O
a	O
cell	O
line	O
derived	O
from	O
human	O
monocytic	O
leukemia	O
cells	O
which	O
can	O
differentiate	O
to	O
macrophage	O
upon	O
stimulation	O
with	O
phorbol	O
ester	O
PMA	O
.	O
Northern	O
blot	O
analysis	O
showed	O
that	O
osteopontin	O
expression	O
is	O
markedly	O
induced	O
in	O
response	O
to	O
PMA	O
.	O
Troglitazone	O
,	O
a	O
PPARgamma	B-protein
ligand	I-protein
,	O
dramatically	O
attenuated	O
the	O
PMA-induced	O
osteopontin	O
expression	O
.	O
Transient	O
transfection	O
assays	O
of	O
the	O
human	O
osteopontin	O
promoter/luciferase	O
construct	O
which	O
contains	O
a	O
5'-flanking	O
region	O
between	O
-1500	O
and	O
+87	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
demonstrate	O
that	O
either	O
treatment	O
with	O
troglitazone	O
or	O
cotransfection	O
of	O
PPARgamma	B-protein
expression	O
vector	O
inhibits	O
osteopontin	O
promoter	O
activity	O
.	O
These	O
data	O
indicate	O
that	O
troglitazone	O
reduces	O
osteopontin	O
gene	O
expression	O
at	O
transcriptional	O
level	O
through	O
PPARgamma	O
activation	O
,	O
and	O
suggest	O
the	O
role	O
of	O
troglitazone	O
in	O
inhibiting	O
the	O
ability	O
of	O
macrophages	O
to	O
produce	O
extracellular	O
matrix	O
,	O
which	O
is	O
particularly	O
relevant	O
to	O
atherosclerotic	O
plaque	O
formation	O
.	O
Transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
regulates	O
Ig	O
lambda	O
light	O
chain	O
gene	O
rearrangement	O
.	O
The	O
tissue-	O
and	O
stage-specific	O
assembly	O
of	O
Ig	O
and	O
TCR	O
genes	O
is	O
mediated	O
by	O
a	O
common	O
V	O
(	O
D	B-protein
)	I-protein
J	I-protein
recombinase	I-protein
complex	I-protein
in	O
precursor	O
lymphocytes	O
.	O
Directed	O
alterations	O
in	O
the	O
accessibility	O
of	O
V	O
,	O
D	O
,	O
and	O
J	O
gene	O
segments	O
target	O
the	O
recombinase	O
to	O
specific	O
Ag	B-protein
receptor	I-protein
loci	O
.	O
Accessibility	O
within	O
a	O
given	O
locus	O
is	O
regulated	O
by	O
the	O
functional	O
interaction	O
of	O
transcription	B-protein
factors	I-protein
with	O
cognate	O
enhancer	O
elements	O
and	O
correlates	O
with	O
the	O
transcriptional	O
activity	O
of	O
unrearranged	O
gene	O
segments	O
.	O
As	O
demonstrated	O
in	O
our	O
prior	O
studies	O
,	O
rearrangement	O
of	O
the	O
Igkappa	O
locus	O
is	O
regulated	O
by	O
the	O
inducible	B-protein
transcription	I-protein
factor	I-protein
NF-kappaB	I-protein
.	O
In	O
contrast	O
to	O
the	O
Igkappa	O
locus	O
,	O
known	O
transcriptional	O
control	O
elements	O
in	O
the	O
Iglambda	O
locus	O
lack	O
functional	O
NF-kappaB	B-protein
binding	O
sites	O
.	O
Consistent	O
with	O
this	O
observation	O
,	O
the	O
expression	O
of	O
assembled	O
Iglambda	O
genes	O
in	O
mature	O
B	O
cells	O
has	O
been	O
shown	O
to	O
be	O
NF-kappaB	O
independent	O
.	O
Nonetheless	O
,	O
we	O
now	O
show	O
that	O
specific	O
repression	O
of	O
NF-kappaB	B-protein
inhibits	O
germline	O
transcription	O
and	O
recombination	O
of	O
Iglambda	O
gene	O
segments	O
in	O
precursor	O
B	O
cells	O
.	O
Molecular	O
analyses	O
indicate	O
that	O
the	O
block	O
in	O
NF-kappaB	O
impairs	O
Iglambda	O
rearrangement	O
at	O
the	O
level	O
of	O
recombinase	O
accessibility	O
.	O
In	O
contrast	O
,	O
the	O
activities	O
of	O
known	O
Iglambda	O
promoter	O
and	O
enhancer	O
elements	O
are	O
unaffected	O
in	O
the	O
same	O
cellular	O
background	O
.	O
These	O
findings	O
expand	O
the	O
range	O
of	O
NF-kappaB	B-protein
action	O
in	O
precursor	O
B	O
cells	O
beyond	O
Igkappa	O
to	O
include	O
the	O
control	O
of	O
recombinational	O
accessibility	O
at	O
both	O
L	O
chain	O
loci	O
.	O
Moreover	O
,	O
our	O
results	O
strongly	O
suggest	O
the	O
existence	O
of	O
a	O
novel	O
Iglambda	O
regulatory	O
element	O
that	O
is	O
either	O
directly	O
or	O
indirectly	O
activated	O
by	O
NF-kappaB	B-protein
during	O
the	O
early	O
stages	O
of	O
B	O
cell	O
development	O
.	O
Transcription	B-protein
factor	I-protein
STAT5A	B-protein
is	O
a	O
substrate	O
of	O
Bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
in	O
B	O
cells	O
.	O
STAT5A	B-protein
is	O
a	O
molecular	O
regulator	O
of	O
proliferation	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
in	O
lymphohematopoietic	O
cells	O
.	O
Here	O
we	O
show	O
that	O
STAT5A	B-protein
can	O
serve	O
as	O
a	O
functional	O
substrate	O
of	O
Bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
(	O
BTK	B-protein
)	O
.	O
Purified	O
recombinant	O
BTK	B-protein
was	O
capable	O
of	O
directly	O
binding	O
purified	O
recombinant	O
STAT5A	B-protein
with	O
high	O
affinity	O
(	O
K	O
(	O
d	O
)	O
=	O
44	O
nm	O
)	O
,	O
as	O
determined	O
by	O
surface	O
plasmon	O
resonance	O
using	O
a	O
BIAcore	O
biosensor	O
system	O
.	O
BTK	B-protein
was	O
also	O
capable	O
of	O
tyrosine-phosphorylating	O
ectopically	O
expressed	O
recombinant	O
STAT5A	B-protein
on	O
Tyr	O
(	O
694	O
)	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
a	O
Janus	B-protein
kinase	I-protein
3	I-protein
-independent	O
fashion	O
.	O
BTK	B-protein
phosphorylated	O
the	O
Y665F	O
,	O
Y668F	O
,	O
and	O
Y682F	O
,	O
Y683F	O
mutants	O
but	O
not	O
the	O
Y694F	O
mutant	O
of	O
STAT5A	B-protein
.	O
STAT5A	O
mutations	O
in	O
the	O
Src	B-protein
homology	I-protein
2	I-protein
(	I-protein
SH2	I-protein
)	I-protein
and	I-protein
SH3	I-protein
domains	I-protein
did	O
not	O
alter	O
the	O
BTK	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
.	O
Recombinant	O
BTK	B-protein
proteins	I-protein
with	O
mutant	O
pleckstrin	O
homology	O
,	O
SH2	B-protein
,	O
or	O
SH3	B-protein
domains	I-protein
were	O
capable	O
of	O
phosphorylating	O
STAT5A	B-protein
,	O
whereas	O
recombinant	O
BTK	B-protein
proteins	I-protein
with	O
SH1/kinase	O
domain	O
mutations	O
were	O
not	O
.	O
In	O
pull-down	O
experiments	O
,	O
only	O
full-length	O
BTK	B-protein
and	O
its	O
SH1/kinase	B-protein
domain	I-protein
(	O
but	O
not	O
the	O
pleckstrin	O
homology	O
,	O
SH2	B-protein
,	O
or	O
SH3	B-protein
domains	I-protein
)	O
were	O
capable	O
of	O
binding	O
STAT5A	B-protein
.	O
Ectopically	O
expressed	O
BTK	B-protein
kinase	I-protein
domain	I-protein
was	O
capable	O
of	O
tyrosine-phosphorylating	O
STAT5A	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
BTK	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
of	O
ectopically	O
expressed	O
wild	O
type	O
(	O
but	O
not	O
Tyr	O
(	O
694	O
)	O
mutant	O
)	O
STAT5A	B-protein
enhanced	O
its	O
DNA	O
binding	O
activity	O
.	O
In	O
BTK	B-protein
-competent	O
chicken	O
B	O
cells	O
,	O
anti-IgM-stimulated	O
tyrosine	O
phosphorylation	O
of	O
STAT5	B-protein
protein	I-protein
was	O
prevented	O
by	O
pretreatment	O
with	O
the	O
BTK	B-protein
inhibitor	I-protein
LFM-A13	I-protein
but	O
not	O
by	O
pretreatment	O
with	O
the	O
JAK3	O
inhibitor	O
HI-P131	O
.	O
B	O
cell	O
antigen	O
receptor	O
ligation	O
resulted	O
in	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
STAT5	B-protein
in	O
BTK	B-protein
-deficient	O
chicken	O
B	O
cells	O
reconstituted	O
with	O
wild	O
type	O
human	O
BTK	O
but	O
not	O
in	O
BTK	B-protein
-deficient	O
chicken	O
B	O
cells	O
reconstituted	O
with	O
kinase-inactive	O
mutant	O
BTK	B-protein
.	O
Similarly	O
,	O
anti-IgM	O
stimulation	O
resulted	O
in	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	B-protein
in	O
BTK	O
-competent	O
B	O
cells	O
from	O
wild	O
type	O
mice	O
but	O
not	O
in	O
BTK	B-protein
-deficient	O
B	O
cells	O
from	O
XID	O
mice	O
.	O
In	O
contrast	O
to	O
B	O
cells	O
from	O
XID	O
mice	O
,	O
B	O
cells	O
from	O
JAK3	O
knockout	O
mice	O
showed	O
a	O
normal	O
STAT5A	B-protein
phosphorylation	O
response	O
to	O
anti-IgM	O
stimulation	O
.	O
These	O
findings	O
provide	O
unprecedented	O
experimental	O
evidence	O
that	O
BTK	B-protein
plays	O
a	O
nonredundant	O
and	O
pivotal	O
role	O
in	O
B	O
cell	O
antigen	O
receptor-mediated	O
STAT5A	O
activation	O
in	O
B	O
cells	O
Role	O
of	O
T-bet	O
in	O
commitment	O
of	O
TH1	O
cells	O
before	O
IL-12	B-protein
-dependent	O
selection	O
.	O
How	O
cytokines	B-protein
control	O
differentiation	O
of	O
helper	O
T	O
(	O
TH	O
)	O
cells	O
is	O
controversial	O
.	O
We	O
show	O
that	O
T-bet	O
,	O
without	O
apparent	O
assistance	O
from	O
interleukin	B-protein
12	I-protein
(	O
IL-12	B-protein
)	O
/	O
STAT4	B-protein
,	O
specifies	O
TH1	O
effector	O
fate	O
by	O
targeting	O
chromatin	O
remodeling	O
to	O
individual	O
interferon-gamma	O
(	O
IFN-gamma	B-protein
)	O
alleles	O
and	O
by	O
inducing	O
IL-12	B-protein
receptor	I-protein
beta2	O
expression	O
.	O
Subsequently	O
,	O
it	O
appears	O
that	O
IL-12	B-protein
/	O
STAT4	B-protein
serves	O
two	O
essential	O
functions	O
in	O
the	O
development	O
of	O
TH1	O
cells	O
:	O
as	O
growth	O
signal	O
,	O
inducing	O
survival	O
and	O
cell	O
division	O
;	O
and	O
as	O
trans-activator	O
,	O
prolonging	O
IFN-gamma	O
synthesis	O
through	O
a	O
genetic	O
interaction	O
with	O
the	O
coactivator	O
,	O
CREB-binding	B-protein
protein	I-protein
.	O
These	O
results	O
suggest	O
that	O
a	O
cytokine	O
does	O
not	O
simply	O
induce	O
TH	O
fate	O
choice	O
but	O
instead	O
may	O
act	O
as	O
an	O
essential	O
secondary	O
stimulus	O
that	O
mediates	O
selective	O
survival	O
of	O
a	O
lineage	O
.	O
Stat6	B-protein
is	O
necessary	O
and	O
sufficient	O
for	O
IL-4	B-protein
's	O
role	O
in	O
Th2	O
differentiation	O
and	O
cell	O
expansion	O
.	O
IL-4	B-protein
plays	O
a	O
critical	O
role	O
in	O
the	O
differentiation	O
of	O
T	O
CR-stimulated	O
naive	O
CD4	O
T	O
cells	O
to	O
the	O
Th2	O
phenotype	O
.	O
In	O
response	O
to	O
IL-4	B-protein
,	O
the	O
IL-4R	B-protein
activates	O
a	O
set	O
of	O
phosphotyrosine	B-protein
binding	I-protein
domain-containing	I-protein
proteins	I-protein
,	O
including	O
insulin	B-protein
receptor	I-protein
substrate	I-protein
1/2	I-protein
,	O
Shc	O
,	O
and	O
IL-4R	B-protein
interacting	I-protein
protein	I-protein
,	O
as	O
well	O
as	O
Stat6	B-protein
.	O
Stat6	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
Th2	O
differentiation	O
.	O
To	O
determine	O
the	O
roles	O
of	O
the	O
phosphotyrosine	O
binding	O
adaptors	O
in	O
Th2	O
differentiation	O
,	O
we	O
prepared	O
a	O
retrovirus	O
containing	O
a	O
mutant	O
of	O
the	O
human	O
(	O
h	O
)	O
IL-4R	O
alpha-chain	O
,	O
Y497F	O
,	O
which	O
is	O
unable	O
to	O
recruit	O
these	O
adaptors	O
.	O
The	O
mutant	O
hIL-4Ralpha	O
,	O
as	O
well	O
as	O
the	O
wild-type	O
(	O
WT	O
)	O
hIL-4Ralpha	O
,	O
was	O
introduced	O
into	O
naive	O
CD4	O
T	O
cells	O
.	O
Upon	O
hIL-4	O
stimulation	O
,	O
Y497F	O
worked	O
as	O
well	O
as	O
the	O
WT	O
hIL-4Ralpha	O
in	O
driving	O
Th2	O
differentiation	O
,	O
as	O
measured	O
by	O
Gata3	O
up-regulation	O
and	O
IL-4	O
production	O
.	O
Furthermore	O
,	O
IL-4-driven	O
cell	O
expansion	O
was	O
also	O
normal	O
in	O
the	O
cells	O
infected	O
with	O
Y497F	O
,	O
although	O
cells	O
infected	O
with	O
Y497F	O
were	O
not	O
capable	O
of	O
phosphorylating	O
insulin	O
receptor	O
substrate	O
2	O
.	O
These	O
results	O
suggest	O
that	O
the	O
signal	O
pathway	O
mediated	O
by	O
Y497	B-protein
is	O
dispensable	O
for	O
both	O
IL-4	B-protein
-driven	O
Th2	O
differentiation	O
and	O
cell	O
expansion	O
.	O
Both	O
WT	O
and	O
Y497F	O
hIL-4Ralpha	O
lose	O
the	O
ability	O
to	O
drive	O
Th2	O
differentiation	O
and	O
cell	O
expansion	O
in	O
Stat6-knockout	O
CD4	O
T	O
cells	O
.	O
A	O
constitutively	O
activated	O
form	O
of	O
Stat6	O
introduced	O
into	O
CD4	O
T	O
cells	O
resulted	O
in	O
both	O
Th2	O
differentiation	O
and	O
enhanced	O
cell	O
expansion	O
.	O
Thus	O
,	O
activated	O
Stat6	B-protein
is	O
necessary	O
and	O
sufficient	O
to	O
mediate	O
both	O
IL-4	B-protein
-driven	O
Th2	O
differentiation	O
and	O
cell	O
expansion	O
in	O
CD4	O
T	O
cells	O
.	O
The	O
effect	O
of	O
HIV-1	B-protein
regulatory	I-protein
proteins	I-protein
on	O
cellular	O
genes	O
:	O
derepression	O
of	O
the	O
IL-2	O
promoter	O
by	O
Tat	O
.	O
In	O
HIV-infected	O
individuals	O
dysregulation	O
of	O
the	O
immune	O
system	O
is	O
characterized	O
by	O
severe	O
disorders	O
of	O
the	O
cytokine	O
network	O
.	O
Increase	O
secretion	O
of	O
IL-2	B-protein
,	O
the	O
major	O
T	O
cell	O
growth	O
and	O
differentiation	B-protein
cytokine	I-protein
,	O
may	O
play	O
a	O
decisive	O
role	O
in	O
sensitization	O
of	O
T	O
cells	O
for	O
activation	O
induced	O
apoptosis	O
and	O
indirect	O
death	O
of	O
activated	O
T	O
cells	O
through	O
augmented	O
virus	O
replication	O
.	O
We	O
investigated	O
the	O
cause	O
of	O
enhanced	O
IL-2	O
secretion	O
and	O
found	O
that	O
the	O
HIV	O
Tat	O
induces	O
this	O
effect	O
.	O
We	O
demonstrate	O
that	O
increased	O
IL-2	O
secretion	O
is	O
due	O
to	O
Tat	O
-enhanced	O
IL-2	O
promoter	O
activation	O
.	O
Tat	O
derepresses	O
and	O
activates	O
the	O
distal	O
AP-1	O
site	O
(	O
position	O
-185	O
to	O
-177	O
)	O
in	O
the	O
IL-2	O
promoter	O
.	O
In	O
nonstimulated	O
T	O
cells	O
a	O
repressor	O
complex	O
containing	O
NF-IL6	B-protein
,	O
JunB	B-protein
,	O
c-Fos	B-protein
and	O
Fra-1	B-protein
is	O
formed	O
on	O
the	O
AP-1	B-protein
(	O
IL-2/d	O
)	O
site	O
and	O
represses	O
IL-2	O
promoter	O
activity	O
.	O
After	O
T	O
cell	O
activation	O
,	O
a	O
heterodimeric	B-protein
activator	I-protein
containing	I-protein
p65	I-protein
and	I-protein
c-Jun	I-protein
binds	O
to	O
the	O
AP-1	B-protein
(	O
IL-2/d	O
)	O
site	O
.	O
HIV	O
Tat	O
enhances	O
activation	O
of	O
NF-kappaB	B-protein
and	O
consequently	O
,	O
activates	O
the	O
AP-1	B-protein
(	O
IL-2/d	O
)	O
site	O
.	O
Our	O
data	O
provide	O
evidence	O
for	O
a	O
novel	O
mechanism	O
by	O
which	O
HIV	O
Tat	O
dysregulates	O
IL-2	B-protein
production	O
and	O
therefore	O
may	O
contribute	O
to	O
the	O
HIV-1	O
infection	O
in	O
a	O
way	O
yet	O
to	O
be	O
clarified	O
.	O
Transforming	O
growth	O
factor-beta1	O
interferes	O
with	O
thrombopoietin-induced	O
signal	O
transduction	O
in	O
megakaryoblastic	O
and	O
erythroleukemic	O
cells	O
.	O
OBJECTIVE	O
:	O
Thrombopoietin	B-protein
(	O
TPO	B-protein
)	O
and	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	I-protein
1	I-protein
)	O
(	O
TGF-beta	O
(	O
1	O
)	O
)	O
have	O
been	O
shown	O
to	O
exert	O
opposite	O
effects	O
on	O
proliferation	O
and	O
megakaryocytic	O
differentiation	O
of	O
hematopoietic	O
cells	O
.	O
To	O
determine	O
whether	O
TGF-beta	O
(	O
1	O
)	O
interferes	O
directly	O
with	O
TPO	B-protein
-induced	O
signal	O
transduction	O
in	O
hematopoietic	O
cells	O
,	O
we	O
compared	O
the	O
regulatory	O
effects	O
in	O
the	O
TPO	B-protein
-responsive	O
cell	O
lines	O
Mo-7e	O
and	O
HEL	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
The	O
cells	O
were	O
stimulated	O
by	O
100	O
ng/mL	O
TPO	B-protein
and/or	O
100	O
ng/mL	O
TGF-beta1	B-protein
and	O
analyzed	O
for	O
proliferation	O
(	O
3H	O
thymidine	O
incorporation	O
)	O
,	O
viability	O
(	O
trypan	O
blue	O
exclusion	O
)	O
,	O
and	O
protein	O
expression	O
and	O
phosphorylation	O
(	O
Western	O
blot	O
)	O
.	O
RESULTS	O
:	O
TPO	B-protein
enhanced	O
the	O
proliferation	O
of	O
Mo-7e	O
cells	O
as	O
determined	O
by	O
3H-thymidine	O
incorporation	O
,	O
whereas	O
TGF-beta1	B-protein
suppressed	O
baseline	O
cell	O
growth	O
and	O
antagonized	O
the	O
proliferative	O
effect	O
of	O
TPO	B-protein
.	O
TPO	B-protein
-induced	O
proliferation	O
also	O
was	O
reduced	O
by	O
a	O
specific	O
inhibitor	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathway	O
(	O
PD098059	O
)	O
,	O
which	O
inhibits	O
activation	O
of	O
the	O
MAPK	B-protein
extracellular	I-protein
signal-regulated	I-protein
kinases	I-protein
(	O
ERK	B-protein
)	O
ERK1	O
and	O
ERK2	B-protein
,	O
and	O
AG490	O
,	O
an	O
inhibitor	O
of	O
Janus	O
kinase-2	O
,	O
which	O
completely	O
blocked	O
TPO	B-protein
-induced	O
proliferation	O
.	O
As	O
demonstrated	O
by	O
Western	O
blotting	O
,	O
TGF-beta1	B-protein
reduced	O
the	O
TPO	B-protein
-stimulated	O
ERK1	B-protein
/	O
ERK2	B-protein
and	O
STAT5	B-protein
phosphorylation	O
in	O
Mo-7e	O
and	O
HEL	O
cells	O
.	O
This	O
effect	O
was	O
completely	O
reversed	O
by	O
preincubation	O
with	O
a	O
tyrosine	O
phosphatase	O
inhibitor	O
(	O
Na3VO4	O
)	O
,	O
which	O
suggests	O
that	O
TGF-beta1	B-protein
activated	I-protein
a	I-protein
phosphatase	I-protein
.	O
Although	O
STAT3	B-protein
also	O
was	O
activated	O
by	O
TPO	B-protein
,	O
STAT3	O
activation	O
remained	O
unaltered	O
by	O
TGF-beta1	B-protein
.	O
CONCLUSION	O
:	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
TGF-beta1	B-protein
modulates	O
TPO	B-protein
-mediated	O
effects	O
on	O
megakaryocytic	O
proliferation	O
by	O
interfering	O
with	O
TPO	B-protein
-induced	O
signal	O
transduction	O
,	O
particularly	O
by	O
reducing	O
the	O
activities	O
of	O
MAPK	B-protein
ERK1/ERK2	I-protein
and	O
STAT5	B-protein
.	O
Invariant	O
chain	O
induces	O
B	O
cell	O
maturation	O
by	O
activating	O
a	O
TAF	O
(	O
II	O
)	O
105-NF-kappaB	O
-dependent	O
transcription	O
program	O
.	O
Early	O
stages	O
of	O
B	O
cell	O
development	O
occur	O
in	O
the	O
bone	O
marrow	O
,	O
resulting	O
in	O
formation	O
of	O
immature	O
B	O
cells	O
.	O
From	O
there	O
these	O
immature	O
cells	O
migrate	O
to	O
the	O
spleen	O
where	O
they	O
differentiate	O
to	O
mature	O
cells	O
.	O
This	O
final	O
maturation	O
step	O
is	O
crucial	O
for	O
the	O
B	O
cells	O
to	O
become	O
responsive	O
to	O
antigens	O
and	O
to	O
participate	O
in	O
the	O
immune	O
response	O
.	O
Recently	O
,	O
invariant	O
chain	O
(	O
Ii	O
)	O
,	O
a	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
II	I-protein
chaperone	I-protein
,	O
as	O
well	O
as	O
the	O
transcription	B-protein
factors	I-protein
c-Rel	B-protein
and	O
p65/RelA	O
,	O
were	O
found	O
to	O
play	O
a	O
role	O
in	O
the	O
final	O
antigen-independent	O
differentiation	O
stage	O
of	O
B	O
cells	O
in	O
the	O
spleen	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
a	O
possible	O
link	O
between	O
Ii	B-protein
-dependent	O
B	O
cell	O
maturation	O
and	O
the	O
NF-kappaB	B-protein
pathway	O
.	O
Our	O
studies	O
indicate	O
that	O
Ii	B-protein
-induced	O
B	O
cell	O
maturation	O
involves	O
activation	O
of	O
transcription	O
mediated	O
by	O
the	O
NF-kappaB	B-protein
p65/RelA	I-protein
homodimer	I-protein
and	O
requires	O
the	O
B	O
cell-enriched	O
coactivator	O
TBP-associated	O
factor	O
(	O
II	O
)	O
105	O
.	O
Androgens	O
indirectly	O
accelerate	O
thymocyte	O
apoptosis	O
.	O
Apoptotic	O
processes	O
,	O
or	O
the	O
disturbance	O
of	O
the	O
natural	O
regulation	O
of	O
these	O
processes	O
,	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
autoimmune	O
diseases	O
(	O
AID	O
)	O
.	O
Women	O
are	O
,	O
in	O
general	O
,	O
more	O
susceptible	O
than	O
men	O
to	O
develop	O
AID	O
like	O
rheumatoid	O
arthritis	O
.	O
Androgens	O
and	O
glucocorticoids	O
,	O
in	O
contrast	O
to	O
oestrogens	O
,	O
have	O
favourable	O
effects	O
in	O
AID	O
models	O
as	O
well	O
as	O
in	O
human	O
AID	O
.	O
It	O
is	O
known	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
,	O
used	O
for	O
treatment	O
of	O
AID	O
,	O
increase	O
apoptosis	O
in	O
the	O
thymus	O
resulting	O
in	O
decreased	O
numbers	O
of	O
CD4+	O
CD8+	O
thymocytes	O
.	O
It	O
was	O
asked	O
whether	O
androgens	O
,	O
in	O
contrast	O
to	O
oestrogens	O
,	O
exert	O
their	O
favourable	O
effects	O
in	O
the	O
treatment	O
of	O
AID	O
by	O
a	O
mechanism	O
comparable	O
to	O
that	O
described	O
for	O
GC	O
by	O
eliminating	O
the	O
apoptosis	O
prone	O
CD4+	O
CD8+	O
population	O
in	O
the	O
thymus	O
.	O
Although	O
both	O
androgens	O
and	O
oestrogens	O
proved	O
thymolytic	O
,	O
a	O
significantly	O
decreased	O
percentage	O
of	O
CD4+	O
CD8+	O
thymocytes	O
was	O
observed	O
by	O
flow	O
cytometry	O
after	O
treatment	O
of	O
mice	O
with	O
the	O
androgen	O
methyltestosterone	O
,	O
but	O
not	O
with	O
the	O
oestrogen	O
ethinylestradiol	O
.	O
To	O
investigate	O
whether	O
the	O
observed	O
thymolytic	O
effects	O
were	O
due	O
to	O
the	O
presence	O
of	O
hormone	B-protein
receptors	I-protein
on	O
thymocytes	O
,	O
cells	O
were	O
isolated	O
from	O
the	O
thymus	O
and	O
incubated	O
with	O
androgens	O
or	O
oestrogens	O
to	O
measure	O
apoptosis	O
.	O
Several	O
techniques	O
were	O
used	O
to	O
determine	O
thymocyte	O
apoptosis	O
in	O
vitro	O
,	O
but	O
no	O
enhanced	O
apoptotic	O
signal	O
was	O
observed	O
.	O
Using	O
the	O
very	O
sensitive	O
TUNEL	O
assay	O
,	O
no	O
direct	O
effect	O
of	O
androgens	O
on	O
thymocytes	O
in	O
vitro	O
could	O
be	O
observed	O
.	O
This	O
is	O
in	O
sharp	O
contrast	O
to	O
the	O
high	O
signal	O
observed	O
with	O
GC	O
.	O
Therefore	O
,	O
upon	O
in	O
vivo	O
androgen	O
treatment	O
,	O
other	O
cells	O
containing	O
androgen	B-protein
receptors	I-protein
than	O
thymocytes	O
are	O
probably	O
involved	O
in	O
inducing	O
the	O
increase	O
in	O
thymic	O
apoptosis	O
.	O
To	O
study	O
the	O
role	O
of	O
the	O
androgen	B-protein
receptor	I-protein
on	O
thymocyte	O
apoptosis	O
,	O
androgen	B-protein
receptor	I-protein
mutant	I-protein
(	O
Tfm/Y	O
)	O
mice	O
were	O
treated	O
with	O
androgens	O
.	O
No	O
alterations	O
of	O
thymocyte	O
subpopulations	O
were	O
seen	O
,	O
suggesting	O
that	O
changes	O
in	O
the	O
percentage	O
of	O
CD4+	O
CD8+	O
thymocytes	O
after	O
administration	O
of	O
androgens	O
depend	O
on	O
the	O
presence	O
of	O
functional	O
androgen	B-protein
receptors	I-protein
.	O
Thus	O
,	O
it	O
is	O
concluded	O
that	O
androgens	O
indirectly	O
accelerate	O
thymocyte	O
apoptosis	O
in	O
vivo	O
.	O
Inhibition	O
of	O
the	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
NF-kappaB	B-protein
in	O
CD4	O
T	O
cells	O
by	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
ligands	O
.	O
The	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	I-protein
PPARgamma	I-protein
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
superfamily	O
,	O
is	O
essential	O
for	O
adipocyte	O
differentiation	O
and	O
glucose	O
homeostasis	O
.	O
PPARgamma	B-protein
has	O
been	O
found	O
recently	O
to	O
regulate	O
macrophage	O
activation	O
in	O
response	O
to	O
mitogens	O
and	O
inflammation	O
.	O
Our	O
study	O
shows	O
PPARgamma	B-protein
to	O
be	O
preferentially	O
expressed	O
in	O
the	O
nuclei	O
of	O
resting	O
T	O
cells	O
and	O
to	O
increase	O
upon	O
activation	O
of	O
T	O
cells	O
by	O
either	O
anti-CD3	O
and	O
anti-CD28	O
or	O
phorbol	O
myristyl	O
acetate	O
(	O
PMA	O
)	O
.	O
We	O
also	O
found	O
the	O
PPARgamma	O
ligand	O
ciglitizone	O
to	O
attenuate	O
the	O
activation	O
of	O
T	O
cells	O
by	O
inhibiting	O
cytokine	O
gene	O
expression	O
and	O
anti-CD3	O
and	O
anti-CD28	O
or	O
PMA-induced	O
proliferative	O
responses	O
.	O
Inhibition	O
of	O
both	O
the	O
proliferative	O
response	O
and	O
inflammatory	O
cytokine	O
expression	O
in	O
CD4	O
T	O
cells	O
was	O
correlated	O
with	O
suppression	O
of	O
the	O
activated	B-protein
transcription	I-protein
factors	I-protein
AP1	B-protein
and	O
NF-kappaB	B-protein
.	O
PPARgamma	O
ligands	O
also	O
strongly	O
inhibited	O
SEA-induced	O
Vbeta3	O
T	O
cell	O
activation	O
in	O
vivo	O
.	O
These	O
results	O
,	O
together	O
with	O
previous	O
findings	O
of	O
the	O
inhibitory	O
effect	O
of	O
PPARgamma	B-protein
ligands	O
on	O
activated	O
macrophages	O
,	O
provide	O
clear	O
evidence	O
for	O
PPARgamma	B-protein
as	O
a	O
negative	O
regulator	O
of	O
the	O
inflammatory	O
activation	O
of	O
both	O
macrophage	O
and	O
T	O
cells	O
.	O
PPARgamma	B-protein
may	O
thus	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
autoimmunity	O
.	O
A	O
prominent	O
role	O
for	O
activator	B-protein
protein-1	I-protein
in	O
the	O
transcription	O
of	O
the	O
human	O
2B4	O
(	O
CD244	O
)	O
gene	O
in	O
NK	O
cells	O
.	O
The	O
cell	O
surface	O
glycoprotein	O
2B4	O
(	O
CD244	O
)	O
of	O
the	O
Ig	B-protein
superfamily	I-protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
NK	O
and	O
T	O
lymphocyte	O
functions	O
.	O
We	O
have	O
recently	O
identified	O
CD48	O
as	O
the	O
high	O
affinity	O
counterreceptor	O
for	O
2B4	O
in	O
both	O
mice	O
and	O
humans	O
.	O
The	O
cytoplasmic	B-protein
domain	I-protein
of	O
2B4	O
associates	O
with	O
src	B-protein
homology	I-protein
2	I-protein
domain-containing	I-protein
protein	I-protein
or	O
signaling	B-protein
lymphocyte	I-protein
activation	I-protein
molecule-associated	I-protein
protein	I-protein
,	O
whose	O
mutation	O
is	O
the	O
underlying	O
genetic	O
defect	O
in	O
the	O
X-linked	O
lymphoproliferative	O
syndrome	O
.	O
In	O
this	O
study	O
,	O
we	O
report	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
the	O
human	O
2B4	O
(	O
h2B4	O
)	O
promoter	O
.	O
Through	O
primer	O
extension	O
analysis	O
,	O
we	O
found	O
that	O
the	O
transcription	O
of	O
the	O
h2B4	O
gene	O
initiates	O
at	O
multiple	O
start	O
sites	O
.	O
We	O
isolated	O
h2B4	O
genomic	O
clones	O
and	O
PCR	O
amplified	O
the	O
5	O
'	O
untranslated	O
region	O
containing	O
the	O
promoter	O
elements	O
.	O
We	O
have	O
identified	O
a	O
functional	O
AP-1	O
site	O
that	O
lies	O
between	O
(	O
-106	O
to	O
-100	O
)	O
through	O
transient	O
transfection	O
analysis	O
in	O
YT	O
cells	O
,	O
a	O
human	O
NK	O
cell	O
line	O
.	O
EMSAs	O
with	O
Abs	O
specific	O
for	O
various	B-protein
protein	I-protein
factors	I-protein
of	O
the	O
AP-1	B-protein
family	I-protein
revealed	O
that	O
multiple	O
members	O
of	O
the	O
Jun	B-protein
family	I-protein
are	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
h2B4	O
gene	O
.	O
Mutation	O
of	O
the	O
AP-1	O
site	O
not	O
only	O
abolishes	O
protein/DNA	O
interactions	O
but	O
also	O
promoter	O
activity	O
.	O
These	O
results	O
demonstrate	O
a	O
significant	O
role	O
for	O
AP-1	B-protein
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
h2B4	O
gene	O
.	O
Functional	O
correction	O
of	O
FA-C	O
cells	O
with	O
FANCC	O
suppresses	O
the	O
expression	O
of	O
interferon	B-protein
gamma-inducible	O
genes	O
.	O
Because	O
hematopoietic	O
cells	O
derived	O
from	O
Fanconi	O
anemia	O
(	O
FA	O
)	O
patients	O
of	O
the	O
C-complementation	O
group	O
(	O
FA-C	O
)	O
are	O
hypersensitive	O
to	O
the	O
inhibitory	O
effects	O
of	O
interferon	B-protein
gamma	I-protein
(	O
IFNgamma	B-protein
)	O
,	O
the	O
products	O
of	O
certain	O
IFNgamma-inducible	O
genes	O
known	O
to	O
influence	O
hematopoietic	O
cell	O
survival	O
were	O
quantified	O
.	O
High	O
constitutive	O
expression	O
of	O
the	O
IFNgamma-inducible	O
genes	O
,	O
IFN-stimulated	O
gene	B-protein
factor	I-protein
3	I-protein
gamma	I-protein
subunit	I-protein
(	O
ISGF3gamma	O
)	O
,	O
IFN	B-protein
regulatory	I-protein
factor-1	I-protein
(	O
IRF-1	O
)	O
,	O
and	O
the	O
cyclin-dependent	O
kinase	O
inhibitor	O
p21	O
(	O
WAF1	O
)	O
was	O
found	O
in	O
FANCC	O
mutant	O
B	O
lymphoblasts	O
,	O
low-density	O
bone	O
marrow	O
cells	O
,	O
and	O
murine	O
embryonic	O
fibroblasts	O
.	O
Paradoxically	O
,	O
these	O
cells	O
do	O
not	O
activate	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	O
1	O
properly	O
.	O
In	O
an	O
attempt	O
to	O
clarify	O
mechanisms	O
by	O
which	O
FA-C	O
cells	O
overexpress	O
IFNgamma-inducible	O
genes	O
in	O
the	O
face	O
of	O
defective	O
STAT1	O
phosphorylation	O
,	O
it	O
was	O
reasoned	O
that	O
decreased	O
levels	O
of	O
activated	O
STAT1	B-protein
might	O
result	O
in	O
reduced	O
expression	O
of	O
a	O
hematopoietic	B-protein
IFNgamma-responsive	I-protein
protein	I-protein
that	O
normally	O
modulates	O
expression	O
of	O
other	O
IFNgamma-responsive	O
genes	O
.	O
Levels	O
of	O
the	O
IFNgamma	B-protein
-inducible	I-protein
factor	I-protein
IFN	I-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
(	O
ICSBP	B-protein
)	O
,	O
a	O
negative	O
trans-acting	O
regulator	O
of	O
some	O
IFNgamma-inducible	O
genes	O
,	O
were	O
quantified	O
.	O
ICSBP	B-protein
levels	O
were	O
reduced	O
in	O
FA-C	O
B	O
lymphoblasts	O
and	O
MEFs	O
.	O
However	O
,	O
enforced	O
expression	O
of	O
ICSBP	B-protein
failed	O
to	O
down-regulate	O
IRF-1	O
,	O
ISGF3gamma	O
,	O
and	O
p21	O
(	O
WAF1	O
)	O
.	O
Thus	O
,	O
the	O
FANCC	O
protein	O
functions	O
to	O
modulate	O
expression	O
of	O
a	O
family	O
of	O
genes	O
that	O
in	O
normal	O
cells	O
are	O
inducible	O
only	O
by	O
specific	O
environmental	O
cues	O
for	O
apoptosis	O
or	O
mitogenic	O
inhibition	O
,	O
but	O
it	O
does	O
so	O
independently	O
of	O
the	O
classic	O
IFN-STAT1	O
pathway	O
and	O
is	O
not	O
the	O
direct	O
result	O
of	O
reduced	O
ICSBP	O
expression	O
.	O
A	O
genetic	O
investigation	O
of	O
E2A	O
function	O
in	O
lymphocyte	O
development	O
.	O
Lymphocytes	O
are	O
derived	O
from	O
hematopoietic	O
stem	O
cells	O
(	O
HSC	O
)	O
following	O
a	O
series	O
of	O
regulated	O
differentiation	O
events	O
.	O
Multipotent	O
HSCs	O
become	O
committed	O
to	O
the	O
B	O
cell	O
lineage	O
in	O
bone	O
marrow	O
and	O
the	O
T	O
cell	O
lineage	O
in	O
the	O
thymus	O
after	O
receiving	O
appropriate	O
signals	O
from	O
the	O
corresponding	O
microenvironment	O
.	O
